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Abstract 
 
X-ray crystallography is the most powerful technique for structural determination of 
proteins, a vital research tool, enabling insight at the atomic level, of the three dimensional 
structure of key protein receptors for potential drug compounds. To be successful, single, 
high quality crystals of the compound in question are required. Current methods to 
produce crystals involve frustratingly long timescales, extensive trial and error using large 
amounts of material, and have no guarantee of success. Polymorphic compounds add 
another level of frustration, requiring the thermodynamic control of crystallisation in order 
to overcome Ostwald’s rule of stages, which considers crystallisation from bulk solution to 
be under kinetic control with metastable polymorphs often crystallising initially. These 
factors have led to what is currently referred to as the “bottle-neck” of protein 
crystallisation, an acute problem1 motivating the rapid development of protein 
crystallisation techniques2. 
 This thesis aims to alleviate the bottle-neck found in protein crystallisation by 
exploring protein crystallisation using microemulsions; a technique, which until now, has 
only been successfully applied to the thermodynamic control of crystallisation for small 
compounds, such as 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (commonly 
known as ROY)3 and glycine4. Through the application of several different surfactant 
systems for the crystallisation of model protein, Lysozyme, this thesis explores the use of 
microemulsions with the aim of producing high quality single crystals suitable for X-ray 
diffraction experiments.  
 Numerous, large, high quality, single crystals of Lysozyme were successfully grown 
using a TritonX-100/1-hexanol surfactant system in which an anti-solvent, mixed 
microemulsion method was applied. Small angle X-ray scattering (SAXS) was effectively 
used to confirm formation of microemulsions and led to the determination of droplet sizes 
using generalised indirect Fourier Transform (GIFT) analysis. X-ray diffraction experiments 
showed single crystals grown from microemulsions to have a high internal order, with the 
resultant data sets of a publishable quality and of a comparative quality to data sets 
collected from crystals grown using standard vapour diffusion crystallisation techniques. 
This thesis demonstrates, for the first time, that microemulsions can be successfully 
used to produce high quality, single crystals of the protein, Lysozyme, shining light on this 
novel technique as a potential means of relieving the bottle-neck of protein crystallisation. 
Future directions of this work include exploring the robustness of the microemulsion 
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crystallisation technique with other proteins such as insulin, glucose isomerase and 
albumin. Expanding this novel technique to the crystallisation of membrane proteins may 
be initially explored through the crystallisation of a 25 residue, membrane spanning part of 
the M2 protein of the influenza virus. This would provide an interesting starting point due 
to the proteins’ biological importance as a target of anti-influenza drugs. 
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Chapter One 
Introduction 
 
The structural characterisation of proteins and small chemical compounds (including 
peptides composed of less than twenty-four amino acids) is deemed highly valuable 
research within both the academic and industrial communities. From a single crystal of the 
compound in question, it is possible to determine the compound’s physical attributes; bond 
length and angles, as well as torsion angles, electrostatic potential and a very good idea 
about intermolecular interactions can be deciphered. The benefits of such knowledge are 
manifold. For a drug molecule to be effective, it must be able to bind to a protein receptor 
site, and hence the protein’s tertiary structure must be known for successful design of drug 
molecules. It is also highly advantageous to obtain structural characterisation of 
pharmaceutical active ingredients (API) as it is important in both drug application and the 
patenting process. The importance is highlighted by the large investment made by 
pharmaceutical companies, which extensively fund research into new drug molecules. The 
importance of obtaining structural information for these molecules is manifold, including 
being able to make predictions of protein ligand interactions through the use of molecular 
modelling5-7. 
 Single crystal X-ray crystallography is by far the most powerful method of structural 
characterisation; enabling the compound’s three dimensional structure to be solved, and 
ideally to a high resolution. This valuable method has led to four Nobel prizes in the last 
twelve years and will be celebrated in the International Year of Crystallography in 20148.  
The three dimensional structure of a compound can be determined provided diffraction-
quality single crystals can be produced. Unfortunately, current methods to produce crystals 
involve frustratingly long timescales with no guarantee of success. Additionally, with 
polymorphic compounds, careful selection of the appropriate crystallisation conditions has 
to be considered in order to obtain a particular polymorph (often the most 
thermodynamically stable form). Failure to crystallise the required crystal form can have 
serious repercussions, as was the case for a marketed anti-HIV drug, Ritonavir9, in 1998. 
Naively, a metastable form of the compound was initially marketed; however, over time, 
the active ingredient transformed to a more stable form which had a reduced 
bioavailability, making the drug less effective. This resulted in Ritonavir being removed from 
the market at a substantial financial cost10. 
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 This thesis will address both chemical and protein crystallisation. For chemical 
crystallisation, commonly used methods of crystallisation will be applied, with the aim of 
using single crystal X-ray diffraction experiments to characterise the structure of the 
crystals produced. This will rely upon successful crystallisation of the compounds, which in 
some cases, is not always guaranteed and often hindered by the small amount of 
crystallisable material available. For protein crystallisation, this thesis pioneers the use of 
microemulsions to determine whether a generic improvement in the protein crystallisation 
methodology is possible.  
 Interest in the application of microemulsions to protein crystallisation stems from 
successful related work, showing an improved quality and stability of small molecule 
crystals can be obtained directly from microemulsions. It has recently been illustrated that 
microemulsion systems can impart thermodynamic control on the crystallisation process. 
Crystallisation from bulk solutions is typically under kinetic control, hence metastable 
polymorphs tend to crystallise first (in accordance with Ostwald’s 1897 rule of stages11, 12 
described in Section 2.3.8). However, in the 3D-nanoconfinement of microemulsion 
droplets, a limited amount of crystallisable material within the droplets means that the 
controlling factor becomes the ability to form stable critical nuclei. Consequently, the more 
thermodynamically stable polymorphs are inherently favoured over higher energy, or less 
crystalline, forms3. This approach has been successfully demonstrated for the crystallisation 
of small molecules4. For this thesis it can be expected that protein crystallisation could be 
enhanced in a similar manner. 
To show that crystallisation in microemulsions offers an improved methodology for 
protein crystallisation, the crystallisation of a commonly used standard protein from 
microemulsions will be compared to its crystallisation using conventional techniques. The 
standard test protein, Lysozyme, is known to crystallise easily. Hen egg-white Lysozyme can 
be crystallised in triclinic, monoclinic, tetragonal and hexagonal crystal forms13. The 
advantage using Lysozyme is all the different crystal forms have been extensively studied 
and hence comparative data is available. X-ray diffraction from crystals grown both by 
standard methods and using microemulsions will be used to draw conclusions with regards 
to the quality of the crystals grown from the two different mediums. 
This thesis begins by detailing in Chapter Two the relevant background related to 
my research project on chemical crystallisation and the crystallisation of proteins from 
microemulsions. Chapter Three then continues to explain methods and experimental 
details used in the attempt to grow crystals for analysis, as well as the implications from the 
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data acquired by X-ray diffraction. Finally, conclusions (Chapter Five) will be drawn from the 
experimental results detailed in Chapter Four, which will be used to lead further research 
being conducted within these areas. 
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Chapter Two 
Background 
 
2.1|  Surfactants 
 
Surface active agents, commonly known as surfactants, are amphiphilic in nature. 
Amphiphilic molecules or ions simultaneously display lipophilic and hydrophilic affinities14. 
There are many substances that can act as surfactants; all share a characteristic molecular 
structure consisting of two distinct moieties: a hydrophilic head group and a hydrophobic 
alkyl chain group (Figure 2.1). Surfactants are of great interest due to their ability to reduce 
interfacial tension and their many potential applications such as detergents and wetting 
agents. 
 
 
Figure 2.1|  A single molecule of a non-ionic surfactant, Span 80, showing the hydrophobic tail group 
and the hydrophilic head group highlighted in grey. 
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2.1.1|  Classification 
 
A primary classification of surfactants is made according to the charge of their hydrophilic 
head groups. There are two main classes: ionic (including anionic, cationic and zwitterionic 
head groups) and non-ionic (which have an uncharged head group) (Table 2.1). The 
hydrophilic head group of a particular surfactant facilitates an enhanced solubility in a range 
of aqueous solvents through hydrogen bonding and electrostatic interactions for non-ionic 
and ionic surfactants respectively15.  
The nature of the hydrophobic tail group has a smaller influence on the qualitative 
behaviour of the surfactant compared to the head group despite the diversity among 
surfactants14. An extensive range of surfactants is available, and much research has been 
undertaken to improve preparation and optimise their physiochemical behaviour for 
specific applications16.  
 
 Example 
Class Schematic structure Name Stucture 
Ionic - Anionic 
 
AOT 
 
Ionic - 
Cationic  
CTAB 
 
Ionic - 
Zwitterionic 
 
EMPIGEN17 
 
Non-ionic 
 
Triton X-100 
 
 
Table 2.1|  Classification of surfactants based on  the charge of the hydrophilic head groups. 
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2.1.2|  Interfacial Tension 
 
An interface is the boundary between two immiscible phases18. The potential energies of 
molecules at the interface are greater than that for the same molecules within the 
respective bulk phases. This is due to the interaction energies at the interface between the 
dissimilar molecules of the two phases. Further, the equivalent difference in potential 
energies requires work to bring a molecule from the bulk phase to the interface. Interfacial 
tension,  , is a measure of this work; it is the minimum amount of work required to create a 
unit area of interface.  
 The change in Gibbs free energy associated with interfacial tension is given by 
Equation 2.119, 
 
                           (2. 1) 
 
where   is the Gibbs free energy of the system,  ,  , and   are the pressure, volume and 
temperature of the system respectively,    is the chemical potential of component  ,    is 
the number of moles of component  ,   is the interfacial tension and   is the interfacial 
area. In a system of fixed composition, at constant temperature and pressure, interfacial 
tension can be described as the Gibbs energy change per unit area of interfacial tension 
(Equation 2.2)19. 
 
        
  
  
 
    
    (2. 2) 
 
High interfacial tension is found between dissimilar phases; however, the 
application of surfactant can be used to reduce interfacial tension. This is a primary 
application of surfactants and is made possible by their amphiphilic nature. 
 
2.1.3|  Properties: Efficiency and Effectiveness 
 
Surfactants are able to reduce interfacial tension by adsorbing at the interface as a result of 
their amphiphilic nature. When added to two immiscible phases, the surfactant molecules 
will arrange so that the hydrophilic head groups are orientated towards the polar, aqueous 
phase and the hydrophobic tails groups towards the non-polar, oil phase. The interactions 
between the hydrophilic and hydrophobic moieties of the surfactant with the respective 
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phases are more favourable compared to the interaction between molecules of the two 
immiscible phases; thus surfactants significantly reduce interfacial tension. 
The tendency to accumulate at interfaces and as a result, the extent of reduction in 
the interfacial tension, differs from surfactant to surfactant. Therefore, choice of surfactant 
is dependent on application. When comparing a particular surfactant’s ability to reduce the 
interfacial tension of a given system, two parameters, efficiency and effectiveness, should 
be considered16, 18.   
Efficiency is related to the bulk phase surfactant concentration required to reduce 
the interfacial tension by a given amount. Efficiency has been found to vary with length of 
hydrophobic alkyl chain length20, 21 and degree of branching22-25. Surfactants with greater 
hydrophobic character and no branching are  the most efficient in the reduction of 
interfacial tension26. For ionic surfactants, the use of a more strongly bound counter ion 
improves efficiency. Positioning of the hydrophilic head group also influences efficiency, 
with a terminal position being most efficient compared to a non-terminal position.  
Effectiveness is the maximum reduction in interfacial tension that can be achieved 
by a particular surfactant irrespective of its concentration and to a large extent is dependent 
on the cohesiveness of the surfactant hydrophobic groups. Branched hydrophobic tail 
groups are therefore more effective as they have lower cohesive forces than straight chain 
hydrophobic tail groups. The effectiveness of surfactants increases when silicone or 
fluorocarbon-based hydrophobic groups are used instead of the more common alkyl chain 
tail groups18. 
 
2.1.4|  Micellisation 
 
A characteristic property of surfactant molecules in solution is their ability to self-assemble 
into micelles, a process referred to as micellisation. Micelles are dynamic aggregates of 
surfactant molecules that form spontaneously at or above the critical micelle concentration 
(CMC).  The CMC is the concentration, at a given temperature and pressure, above which 
micellisation can occur. The CMC may vary with temperature and pressure. For a solution of 
anionic surfactant, measurements of electrical conductance indicate the absence of 
aggregation when there is a low surfactant concentration. There is a sharp reduction in 
conductance (Figure 2.2) when surfactant concentration reaches a particular value, the 
CMC, indicating the formation of micelles16. Above the CMC, the surfactant concentration in 
solution is effectively constant; excess surfactant aggregates into micelles which are in 
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dynamic equilibrium with the monomer surfactant in solution27. Changes in other physical 
properties, such as turgidity and surface tension, can also be used to determine the CMC of 
a particular surfactant28.  
 
Figure 2.2|  Plot of equivalent conductivity (specific conductance per gram-equivalent of solute) 
against the square root of the normality of solution (gram equivalent weight of a solute per litre of 
solution). The sharp decline in conductance for the surfactant solution indicates the point of micelle 
formation. Adapted from Rosen
16
.  
 
For spherical micelles (Figure 2.3a) in a polar solvent such as water, the hydrophobic 
tails of the surfactant molecules are contained within the interior of the micelle and the 
hydrophilic head groups are orientated towards the bulk aqueous solution29-31. Reverse 
micelles (Figure 2.3b) are formed in bulk oil solutions where the hydrophilic head groups are 
orientated away from the oil. Other structural forms of micelles include cylindrical micelles 
and bilayers (Figure 2.3c and d). Micellar shape can be predicted by the packing parameter 
(Table 2.2) of the particular surfactant32. The packing parameter is given by            , 
which is the ratio of the volume of the surfactants hydrophobic chain ,  , to the product of 
effective surfactant length,   , and the effective head group surface area,   , which reflects 
the size and charge of the head group and its surrounding electrostatic environment33. 
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Figure 2.3|  Shapes of surfactant aggregates: a) spherical micelle, b) spherical reverse micelle, c) 
cylindrical micelle, d) bilayer. 
 
 The free energy change of micelle formation,    , is given by Equation 2.3, where 
  is the temperature of the system and     and     are the enthalpy and entropy 
changes for micellisation respectively34.  
 
                    (2. 3) 
 
These parameters can be determined from the temperature dependence of the CMC or 
measured directly by using microcalorimetry. Micellisation is spontaneous and 
thermodynamically favoured when      is large and negative under the given conditions. 
At room temperature, hydrophobic interactions are the main driving force for micelle 
formation34. As surfactant concentration is increased above the CMC, the release of water 
molecules from ordered shells of hydration that surround the hydrophobic surfactant tails 
results in a large entropic gain. Other models such as ‘Phase Separation’ and ‘Mass Action’ 
can also be used to describe micelle formation31, 35. 
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Packing Parameter Micelle Shape 
   
 
 
 Spherical 
 
 
    
 
 
 Cylindrical 
 
 
      Bilayer 
     Reverse 
 
Table 2.2|  Typical shape of surfactant aggregates based on the packing parameter,   , of the 
surfactant. Adapted from Tolbert et al
36
. 
 
2.1.5|  The Krafft Point 
 
The Krafft point, also known as the Krafft temperature,   , is commonly observed in ionic 
surfactants but rarely in non-ionic surfactants37. Philips defined the Krafft point as the 
temperature at which a surfactant’s solubility is equal to its critical micelle concentration 
(CMC)38. Below the Krafft point, surfactants display a low solubility and tend not to form 
micelles. At, the Krafft point and above, there is a steep increase in the solubility of the 
surfactant due to the occurrence of surfactant micellisation39. 
To determine the Krafft point of a particular surfactant, measurements of its CMC 
and solubility with changing temperature are required. The point of intersection between a 
solubility curve and CMC curve makes clear the concept of the Krafft point as shown in 
Figure 2.4. 
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Figure 2.4|  Changes in the solubility and the CMC as temperature is increased. The point of 
intersection between the two curves is defined as the Krafft temperature,   . Adapted from
27
. 
 
The Krafft point varies with surfactant hydrophobic chain length, extent of 
branching40, bulkiness of the hydrophilic head group and addition of a counter-ion31. When 
selecting a surfactant for a particular application it is important to consider its Krafft point, 
as below    a surfactant is significantly less effective and micellisation is not permitted. 
 
2.1.6|  The Cloud Point 
 
Observed in non-ionic surfactants, the cloud point is the temperature at which a surfactant 
solution phase separates into surfactant-rich and surfactant-deficient phases. Clouding can 
affect solutions of ionic surfactants41, 42, but is predominantly observed for non-ionic 
surfactants. As the cloud point is approached, the hydrophilic head groups of micelles are 
dehydrated, and non-ionic surfactant micelles aggregate to form clusters43  via an attractive 
potential, whose well-depth increases with temperature44. The cloudy appearance of a 
surfactant solution, at or above its cloud point, is due to the scattering of light by the 
micellar aggregates.  
There is currently limited knowledge about the mechanism that results in the 
observed phase separation when the cloud point of a surfactant solution is reached.  Initial 
explanations focused on a transition of micellar expansion from a globular shape to an 
enlarged rod-like shape45. However this remains a contentious explanation. More recently, 
A. Zliman and H. Bock attribute phase separation to the formation of a connected micellar 
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network or directional hydrogen bonding between surfactant head groups and molecules of 
water respectfully46, 47. 
Variables such as structure and concentration of surfactant and the presence of 
additives, such as electrolytes or organic molecules, have been found to affect the cloud 
point of surfactants43. Fritz investigated the effect of surfactant chain length, and found the 
cloud point decreased with increasing carbon chain length48. Changes in pressure may also 
result in clouding49, 50.  
 
2.2|  Emulsions 
 
Emulsions are conventionally described as a dispersion of one liquid in another, where both 
liquids are either mutually immiscible with one another or poorly miscible51. Depending on 
the droplet size, three categories of emulsion can be defined. Macro-emulsions (Figure 2.5a) 
have a droplet size of approximately ≥400 nm and are white and cloudy in appearance, 
nano-emulsions (Figure 2.5b) have a droplet size of approximately 50-200 nm52, 53 and 
appear blue and cloudy, and microemulsions (Figure 2.5c) have a droplet size of typically 2-
1-100 nm54 and are transparent.  
 
 
Figure 2.5|  The transparency of an emulsion depends on the size of the droplets. a) Macro-emulsion 
b) Nano-emulsion c) Microemulsion. 
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Macro-emulsions are thermodynamically unstable55 due to an inherent positive free 
energy of formation.  Thus, after a finite time, they will separate into two or more phases. 
Separation of emulsions, which are non-equilibrium systems, is due to the unfavourable 
high specific surface areas caused by the process of dispersion of one phase into another 
immiscible phase51. Emulsions may degrade into two or more phases via a number of 
different mechanisms56  as summarised in Figure 2.6. Coalescence is the predominant 
mechanism of degradation for many emulsion systems; however, Ostwald ripening can be a 
significant factor, but is often neglected56. Oswald ripening occurs due to the difference in 
chemical potentials of materials confined within small droplets compared to material within 
larger droplets. This causes emulsion droplets of a significant size to grow larger at the cost 
of the smaller droplets. Differences in chemical potentials arise due to the differences in the 
radius of curvature of the droplets. 
 
Figure 2.6|  Schematic representation of mechanisms of emulsion degradation. Adapted from 
Taylor
56
. 
 
There have been extensive efforts to try and increase the stability, and thus lifetime 
of macro-emulsions. Such stability is required in macro-emulsions as they are used by 
industry for a broad range of applications including acting as carriers for drug molecules57, 58 
and pesticides59.  
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2.2.1|  Hydrophilic-lipophilic Balance (HLB) 
 
HLB, the hydrophilic-lipophilic balance, was first introduced in 1949 by Griffin60. HLB is an 
arbitrary scale that assigns a numerical value to individual surfactants indicating the balance 
of the strength and size of the surfactants’ hydrophilic and hydrophobic moieties. For 
particular applications, considering the HLB of potential surfactants enables one to predict 
whether an oil-in-water emulsion or a water-in-oil emulsion will form in a given system60 . 
Surfactants with HLB values of less the 10 typically form w/o-emulsions, whereas those with 
HLB values greater than 10 typically form o/w-emulsions. Table 2.3 summaries expected 
functions of surfactants based on their HLB values61. 
 
Surfactant HLB Number Expected application of Surfactant 
1.5-3 Anti-foaming agent 
1-4 Emulsifier for w/o emulsions 
6-8 Wetting agents 
10-13 Emulsifier for o/w emulsions 
13-15 Detergent 
15-18 Solubiliser 
 
Table 2.3|  Expected application of surfactants given their assigned HLB value. Adapted from 
Kruglyakov
61
. 
 
Griffin first developed an empirical formula (Equation 2.4) for calculating the HLB of 
non-ionic alkyl polyglycol ethers based on the weight percentages of ethylene oxide and 
hydroxide groups,       and     , respectively. 
 
        
           
 
    (2. 4) 
 
Davies and Rideal62 further developed Griffin’s initial concept to create a general empirical 
equation (Equation 2.5) to define HLB in terms of numerical values assigned to the chemical 
groupings present in the surfactant molecule.  
 
                                                   (2. 5) 
 
If more than one surfactant is used, the HLB of the blend can easily be calculated using an 
additive approach60. For example, a surfactant blend composed of 25% surfactant A with 
HLB 4 and 75% surfactant B with HLB 14 would have an overall HLB value of 11.5. HLB values 
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(along with other influencing factors) of the surfactants used in thesis have been considered 
in order to obtain water in oil microemulsion systems. 
  
2.2.2|  Phase Inversion Temperature (PIT) 
 
The stability of emulsions formed from a surfactant system, are highly temperature 
dependent. Water-continuous emulsions are most stable at a low temperature, and oil-
continuous emulsions are most stable at higher temperatures. This is because the extent of 
hydration around the hydrophilic surfactant head groups decreases as temperature is 
increased. Consequently, the hydrophilic nature of a surfactant decreases as temperature 
increases16. PIT, the phase inversion temperature, is defined as the temperature at which a 
particular non-ionic surfactant system switches from an o/w emulsion to a w/o emulsion. 
Unlike HLB, which is a parameter regarding an individual surfactant independent of the 
system, PIT is a parameter concerning the whole system. There is an approximately linear 
relationship between PIT and HLB; increasing the chain length on a surfactant results in both 
a higher HLB and PIT value.  
The nature of the oil used, the ratio of oil to water, and the use of additives (such as 
salts) all influence the PIT31. Oil additives such as fatty acids or alcohols, which increase the 
polarity of the oil, result in a significant reduction in the PIT. Figure 2.7 demonstrates the 
effect that such factors have on an emulsion system, highlighting the change in curvature at 
the oil-water interface and the change in position of the surfactants tail group across the 
interface. At the PIT, the interfacial tension between oil and water is found to be at a 
minimum.  
 
Figure 2.7|  Schematic representation of the effect of temperature, oil polarity and electrolyte 
concentration on the PIT, where ‘o’ and ’w ’indicate oil and water phases respectively. Adapted from 
Jönsson et al
31
. 
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2.2.3|  Nano-emulsions 
 
Emulsions with droplet sizes of approximately 50-200 nm are commonly and most 
favourably known as nano-emulsions53, 63 but they are also referred to as mini-emulsions64 
or sometimes submicron emulsions65. Due to their small droplet size, nano-emulsions 
appear translucent or transparent with a blue tint (due to scattering of light) (Figure 2.5b) 
and present stability towards creaming. They are more kinetically stable then macro-
emulsions; however, they are not thermodynamically stable.  
Nano-emulsions are non-equilibrium systems and do not form spontaneously under 
ambient conditions63. To form small droplets, energy and/or large amounts of surfactant are 
required.  The Laplace pressure,  , which is the difference in pressure between the inside 
and outside of a nano-emulsion droplet, can aid understanding when considering the large 
amount of energy required to form nano-emulsions compared to macro-emulsions53. The 
Laplace pressure  , is given by Equation 2.6, where    and    are the droplet radii of 
curvature and   is interfacial tension.             for spherical drops, reducing to 
Equation 2.7. 
 
         
 
  
 
 
  
     (2. 6) 
 
      
  
 
    (2. 7) 
 
Considering the inverse relationship, it is apparent that the Laplace pressure increases as a 
droplet is deformed to create smaller droplets; this can be demonstrated when a spherical 
droplet deforms to form a prolate ellipsoid. The stress needed to deform a drop is greater 
for smaller drops due to a spherical drop having one radius of curvature and a prolate 
ellipsoid having two radii of curvature. More energy is required to produce smaller drops as 
more vigorous agitation from the surrounding liquid is required when the stress is greater66. 
As previously mentioned in Section 2.1.2 addition of surfactants will lower the interfacial 
tension, thus facilitating the formation of nano-emulsions as   is reduced with a decrease in 
 . To assist the preparation of nano-emulsions, numerous methods have been developed 
including application of the PIT concept, high pressure homogenisers and the employment 
of the low energy emulsification method at constant temperature53.  
Nano-emulsions have many diverse applications; including the provision of an 
encapsulation medium for delivery of antimicrobial essential oils67, as a medium for the 
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production of polymeric nano-particles, and a method known as the mini-emulsion 
polymerisation, which considers nano-emulsion droplets as nano-reactors68. The appeal of 
nano-emulsions in such applications is manifold, including their stability against 
sedimentation or creaming and their ability to remain a dispersed system due to their small 
droplet sizes preventing flocculation. 
 
2.2.4|  Microemulsions 
 
Microemulsions are thermodynamically stable69, self-aggregated systems. Macroscopically, 
they are homogeneous mixtures of water, oil and surfactant. However, at a microscopic 
level, microemulsions consist of a colloidal dispersion of water-rich or oil-rich domains 
separated by a film of amphiphilic molecules70. In some systems a co-surfactant is also used. 
Microemulsions form spontaneously and, at equilibrium, will have droplet sizes of 1-100 
nm54. Small droplet sizes reduces scattering of visible light, leading to their transparent 
appearance. Microemulsions are of great interest due to their chemical and physical 
stability, enabling long-lived stability of mixed oil and water systems which cannot be 
achieved through the use of macro-emulsions. 
 The micellisation process during the formation of microemulsions can be described 
using Equation 2.871, where     is the free energy of formation,   is the interfacial tension, 
   is the change in interfacial area, temperature is denoted   and    the change in 
entropy. Formation is favourable when        ; therefore, microemulsions will form 
when an ultra-low interfacial tension is achieved which compensates for the large change in 
interfacial area that occurs due to the formation of droplets.  
 
                  (2. 8) 
 
Since microemulsions were first described in 1943 by Schulman72, extensive 
research has been facilitated by the development of experimental characterisation 
techniques such as small-angle X-ray scattering (SAXS), small-angle neuron scattering (SANS) 
and electron microscopy73. As a result, an extensive knowledge of microemulsion structure 
has been established and today work continues to explore the potential applications of 
microemulsions74. 
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2.2.5|  Microemulsions: Microstructure and Classification  
 
In 1948, Winsor first described four classifications of equilibrium microemulsion systems 
composed of water (or aqueous salt solution), oil (a mixture of single organic liquid) and 
approximately 5-25% of surfactant75. Figure 2.8 depicts these four classes which he 
described as: Winsor I, a phase separated system with an upper excess oil phase and a 
lower o/w microemulsion; Winsor II, a phase separated system with an upper w/o 
microemulsion and a lower excess water phase; Winsor III, a triple layer system with an 
upper excess oil phase, a lower excess water phase and a middle biscontinuous 
microemulsion phase; and Winsor IV, a homogeneous system consisting of one 
microemulsion phase70. Depending on the conditions, this single phase can be an o/w 
microemulsion consisting of normal micelles or a w/o microemulsion consisting of reverse 
micelles. The four Winsor equilibrium systems described can interconvert between one 
another depending on the conditions.  
 
Figure 2.8|  Schematic representation of the four Winsor classifications of microemulsions. Different 
phases are highlighted in different shades of grey; pale grey indicates an Oil (O) phase, dark grey 
indicates a Water (W) phase, medium grey indicates a microemulsion phase. The type of 
microemulsion phase varies depending on the Winsor type; O/W indicates oil-in-water 
microemulsion, W/O indicates a water-in-oil microemulsion. Winsor type IV could be each of the 
different microemulsion forms, W/O, biscontinuous or O/W. 
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2.2.6|  Co-surfactant 
 
A co-surfactant is often used to aid stability of microemulsions and support the dispersion of 
surfactant molecules at the interface between the oil and water phases76. Weakly 
amphiphilic molecules such as medium and long chain alcohols are typically used as co-
surfactants alongside the primary surfactant to lower the interfacial tension. However, in 
some circumstances short chain alcohols such as methanol also prove effective4. 
 For ternary microemulsions (those without a co-surfactant) extensive investigations 
exploring their microstructures have shown good agreement between theory and 
experiments when considering changes in parameters such as salinity of the aqueous phase 
or temperature. However, there is limited understanding for quaternary microemulsions in 
which the co-surfactant may partition among the oil, aqueous and interface domains 
instead of exclusively residing at the interface as seen in ternary microemulsion systems. A 
quantitative description of the dependence of a quaternary systems composition on the 
partition equilibria is crucial to gaining a greater understanding of quaternary 
microemulsions. Palozo et al in 2003 investigated the interfacial composition of 
CTAB/water/n-pentanol/n-hexane microemulsions, and quantitatively discussed the w/o 
droplet size in terms of surface composition and water content for a wide range of system 
compositions77.  Using PGSE-NMR experiments, it was found that n-pentanol partitions 
strongly at the interface. The composition of the interface could be described to be 
dependent on the overall composition using a simple partition equilibrium. The total 
interface area was found to increase and the film thickness to decrease as the amount of n-
pentanol was increased. The amount of water in the quaternary microemulsions was also 
found to have an effect, resulting in an increase of reverse micellar radii as more water was 
added. Over the experimental composition range used only inverse micellar structures were 
observed.  
Within this investigation, a co-surfactant of 1-hexanol will be used with surfactant 
TritonX-100, to create a surfactant system which will support the formation of reverse 
micelles in a stable microemulsion system for the crystallisation of Lysozyme (Section 
3.2.2.3 and 4.4.7).  
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2.2.7|  Surfactant Film Spontaneous Curvature 
 
Aggregates of surfactant within microemulsions can be considered to be composed of 
surfactant films. The curvature of such films influences the structures of the resultant 
aggregates. Alongside spontaneous curvature,   , the volume fractions of oil and water also 
govern whether a w/o or o/w microemulsion is formed78. Spontaneous curvature is the 
inverse of the radius of curvature and is defined to be negative if the surfactant film is 
curved around the hydrophilic domain or positive if it is curved towards the hydrophobic 
domain31, as demonstrated in Figure 2.9. Overall a surfactant film is flexible, displaying 
regions of both positive and negative curvature. A spontaneous curvature close to zero 
shows that the film has little curvature towards either of the aqueous or non-polar phases. 
Planar films such as lamellar, bicontinuous phases and sponge-like phases all exhibit zero 
spontaneous curvature. Droplet microemulsions are the most common structure observed 
in microemulsions78. Normal micelles formed in o/w microemulsions will have a positive film 
curvature and reverse micelles in w/o microemulsions will have a negative film curvature.  
 
Figure 2.9|  Spontaneous curvature is defined to be positive or negative depending on which way the 
surfactant film curves around the hydrophilic domain. 
 
The type of microemulsion formed can be manipulated by varying the spontaneous 
curvature. By lowering the repulsions between surfactant head groups, which can be 
achieved for ionic surfactants by using electrolyte additives, spontaneous curvature can be 
decreased. Spontaneous curvature can be more readily controlled in ternary microemulsion 
systems compared to quaternary systems which incorporate a co-surfactant. In such 
systems    depends on the surfactant/co-surfactant ratio at the interface which can be 
varied by altering the surfactant/co-surfactant ratio in the overall mixture with the aqueous 
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and non-polar phases. However, as previously mentioned in Section 2.2.6, co-surfactants 
can partition in both immiscible phases thus resulting in little to no control. 
 
2.2.8|  Bending Elasticity of the Surfactant Film 
 
Understanding the phase behaviour of surfactant systems, and trying to select a particular 
micellar structure from, requires consideration of numerous parameters including simple 
packing and energy considerations. The bending elastic energy of a surfactant film 
contributes to the free energy of the surfactant systems. The contribution of the surfactant 
film to the free energy (per unit area) is given in Equation 2.978, where    and    are the 
principal curvatures of the surfactant films,    is the spontaneous curvature, and   and   
are the mean and Gaussian bending elastic constants. To describe the elastic properties of a 
surfactant film the two elastic constants,         are required.  
 
 
     
 
 
            
          (2. 9) 
 
Gradzielski noted the importance of determining the elastic constants in order to 
attain understanding of the behaviour and properties of microemulsions. As a result, in 
1996 Gradzielski et al conducted a study of a simple system which could be varied 
systematically in order to investigate how parameters such as the chain length of the 
surfactant influenced the elastic constants79. They found that the elastic theory of the 
surfactant film aided understanding of microemulsion microstructure and macroscopic 
properties such as interfacial tension by observing that macroscopic interfacial tension, 
droplet radii and polydispersity index could be related to   and  . The sum,     , was 
found to scale approximately with surfactant chain length to the power of three; the oil 
hydrocarbon chain length was found to have little influence on the elastic constants.  
   
2.2.9|  Phase Behaviour 
 
A phase can be defined as a region of space filled homogenously with a physically distinctive 
form of matter. Light, neutron and X-ray scattering techniques can be used to distinguish 
between phases based on their diffraction properties. More simply, viscosity can be used to 
distinguish phases; however, this cannot be used as an unambiguous method since viscosity 
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is dependent on concentration and surfactant. For droplet phases, a distinction between 
reverse or normal micelles can be made based on composition, as characteristically reverse 
micelles form in an oil-rich environment and normal micelles form in a water-rich 
environment31. 
Gibbs introduced the phase rule as defined in Equation 2.10, where   is the number 
of phases that coexist,   is the number of components that constitute the system and   is 
the number of degrees of freedom.  
 
                (2. 10) 
 
Within a microemulsion, the degrees of freedom include temperature, pressure and 
composition variables. For the purposes of this discussion pressure will be considered to be 
constant, thus reducing the number of degrees of freedom by one.  
Phase diagrams enable the schematic representation of a microemulsion’s phase 
equilibria, depicting how many phases there are present in a system, what the phases are 
and detailing the composition of the phase in question. Completing a phase diagram 
becomes increasingly difficult as the number of components within a system increases. 
Typically, a three component phase diagram, also known as a ternary phase diagram, is used 
to describe a microemulsion which includes an aqueous phase, oil phase and surfactant 
phase. If co-surfactant is required, a pseudo-ternary phase diagram can be used in which 
one of the three components consists of a mixture of surfactant and co-surfactant at a fixed 
ratio. It is often useful to consider phase behaviour at a fixed temperature as depicted in 
Figure 2.10a. Considering the temperature dependence of phase behaviour gives rise to a 
triangular prism consisting of stacks of isothermal phase diagrams (Figure 2.10b and c). 
Different cuts through the triangular phase prism can be made in order to understand the 
effects that different microemulsion components have on phase behaviour. Such cuts 
include the Lund cut80, which gives a fixed ratio between the surfactant and oil phases while 
varying the water content (Figure 2.10b), and the Kahlweit fish cut81, which gives a fixed 
ratio between the water and oil phases (typically 1:1) while varying surfactant concentration 
(Figure 2.10c). The Kahlweit Fish phase diagram (Figure 2.10d) enables information 
regarding the surfactants’ effectiveness to be inferred82.  
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Figure 2.10|   a) Pseudo ternary phase diagram at fixed temperature; b) Lund cut through phase 
prism; c) Kahlweit fish cut through phase prism; d) Kahlweit fish phase diagram. 
 
 Pseudo ternary phase diagrams of the form pictured in Figure 2.10a are the most 
appropriate phase diagram for the aims of this investigation. These phase diagrams will aid 
selection of suitable composition ratios that will enable the formation of stable 
microemulsions for each surfactant system explored (Section 3.2.2.1).  
 
2.2.10|  Microemulsions: Droplet Polydispersity 
 
There is a slight droplet polydispersity observed in microemulsions which can be measured 
using electrical birefringence experiments83. Such polydispersity is an equilibrium property78 
due to the thermodynamic stability of the microemulsion micellar phase. Polydispersity is 
partially a result of droplet collisions which result in the formation of transient aggregates, 
also referred to as transient dimers. The formation of transient aggregates allows transfer of 
solubilised materials from droplet to droplet. The transient droplets have a short life-time, 
typically of the order of microseconds. However, if there exists attractive interactions 
between droplets, the transient dimer’s life-time may be slightly extended84. For the 
purpose of the following investigation discussed in this thesis, droplets will be assumed to 
be relatively monodisperse.  
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2.2.11|  Applications of Microemulsions 
 
The applications of microemulsions across both academic research and industry have been 
extensively explored and reviewed74 . Interest in microemulsions accelerated following their 
use in enhanced oil recovery74, 85, 86, in which approximately 20% of otherwise unrecovered 
underground oil was obtained using a process referred to as surfactant-polymer flooding. In 
this process, the high interfacial tension between crude oil and reservoir brine, which 
caused oil to remain trapped in porous material underground, was reduced through the 
formation of a middle-phase microemulsion in situ between crude oil and excess reservoir 
brine.  
 Exploring further, microemulsion fuels have successfully been shown to reduce soot 
formation and the emission rates of nitrogen oxides and carbon monoxide during 
combustion of microemulsion fuels87. Other applications of microemulsions include their 
use in cosmetics88 and as a chemical reaction medium, the first use of which was in 1973, 
where microemulsions were used to accelerate the hydrolysis of esters89. More recently, 
interest in microemulsions has grown based on their ability to provide thermodynamic 
control for crystallisation of polymorphic compounds3 . 
 
2.3|  Crystallisation 
 
The development of X-ray crystallography, a valuable tool for structure determination, has 
called for an in-depth understanding of the process of crystallisation and for the design of 
suitable methods that will yield single crystals of a high quality appropriate for X-ray 
diffraction experiments. Preparative methods of compounds of interest often yield the 
product in a ‘crystalline’ form but frequently such crystals are of an insufficient quality. 
Appropriate quality crystals typically have well formed, clear faces and will shine brightly 
when viewed with polarised light under a microscope. An exception to this observation 
occurs for crystals of high symmetry and for those that are cubic90. Although visually some 
crystals may appear of a good quality, it is their internal order which determines their 
diffraction pattern. Only crystals which are internally ordered will produce diffraction 
patterns.  For membrane proteins it is quite common to produce visually pleasing objects; 
however, they often have very little internal order and this diffract poorly91.  
Crystallisation comprises of two stages: nucleation and crystal growth92. The 
occurrence of nucleation is a prerequisite for crystal growth to take place. Each 
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crystallisation method aims to create a supersaturated solution (a solution in which the 
solubility limit of the crystallisable material is exceeded) as this facilitates the formation of 
nucleation sites. This section will lay out the fundamental scientific principles that dictate 
crystallisation and highlight the wealth of crystallisation techniques available for crystallising 
both proteins and small molecules.  
 
2.3.1|  Nucleation and Supersaturation 
 
A prerequisite for crystallisation to occur is nucleation. Nucleation is the phase change from 
solution to solid at a localised point; it results in the formation of small clusters of building 
units consisting of regularly ordered molecules associated in identical orientations. How 
many nucleation events take place in a solution is influenced by several variables including 
temperature, pressure and the concentration of the solution. The continued adsorption of 
the specimen molecules to the surface of the critical nuclei will result in the growth of a 
single crystal given that the molecules adsorb in an identical orientation.  
 Nucleation is strongly influenced by a solution’s degree of supersaturation. 
Supersaturation is a metastable state (Figure 2.11) where the system is not in equilibrium93. 
The solution in the metastable region has more dissolved compound compared to a 
saturated solution which is in equilibrium. If nucleation overcomes an activation barrier, 
which enables the metastable system to move towards equilibrium, the dissolved 
compound will precipitate out of solution (ideally in a crystalline state, but this may not be 
the case). The newly formed precipitate will then be in equilibrium with the saturated 
solution which subsequently forms. The stability condition (Equation 2.11) 
thermodynamically defines the limits of the metastable region of supersaturation where    
is the mean molar Gibbs energy of the system and    is the molar fraction of the sample 
compound.  
 
      
    
   
        (2. 11) 
 
Spontaneous decomposition of a solution results by further increasing the concentration of 
the sample compound to form an extremely supersaturated solution (Point A in Figure 
2.11). At this point the second derivative in Equation 2.11 becomes negative. 
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Figure 2.11|  Crystallisation phase diagram. The region of supersaturation in which nucleation can 
occur is highlighted grey. Point A marks the area in which the crystallisable material is likely to crash 
out of solution as a result of the solution being extremely supersaturated.  
 
2.3.2|  Homogeneous Nucleation 
 
Nucleation that occurs spontaneously in the interior of a pure supersaturated solution is 
termed homogeneous nucleation. The total Gibbs free energy change associated with 
homogeneous nucleation, which leads to the formation of a spherical critical nuclei of radius 
 , can be described by Equation 2.1294, where    is the number-density of the newly formed 
nuclei and   is the interfacial tension of the newly formed solid-liquid interface.  
 
       
 
 
           
     (2. 12) 
 
The chemical potential,    (               ), is the difference between the 
chemical potential of the solid phase,        the liquid phase,   . The change in Gibbs free 
energy (Equation 2.12) consists of two terms: the ‘bulk’ term (
 
 
       ) and the ‘surface’ 
term (     ). The bulk term is negative and proportional to the volume of the nuclei; it 
conveys the greater stability of the newly formed solid compared to the supersaturated 
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solution. The loss of free energy due to the formation of a solid-liquid interface is accounted 
for by the surface term, which is negative and proportional to the surface area of the 
nuclei94.  
 If a system experiences free energy fluctuations that have insufficient free energy to 
form nuclei of a critical size, the nuclei are likely to re-dissolve instead of growing into 
crystals. Nuclei that do not re-dissolve have a radius of    and are termed critical nuclei. The 
Gibbs free energy for the formation of critical nuclei is a maximum value. The radius    can 
be determined using the Gibbs-Thomson equation (Equation 2.14) which is found by setting 
the first derivative of    with respect to   to zero (Equation 2.13).  
 
    
   
  
                   (2. 13) 
 
        
  
      
    (2. 14) 
 
 Substituting Equation 2.14 into Equation 2.12 gives the Gibbs free energy of 
formation for a critical nucleus,     (Equation 2.15). The formation of critical nuclei of 
radius ≥    will result in further crystal growth. 
 
         
     
          
   (2. 15) 
 
Within the microemulsion systems detailed in this thesis it is hoped that 
homogeneous nucleation will be facilitated within the microemulsion droplets, resulting in 
the formation of critical nuclei of radius ≥   and thus supporting the subsequent growth of 
Lysozyme crystals.  
 
2.3.3|  Heterogeneous Nucleation 
 
Typically, it is undesirable for nuclei to form on the wall of the reaction vessel. This occurs 
when nucleation is stimulated by the presence of impurities such as ions, foreign surfaces 
and particles. Such a process is known as heterogeneous nucleation95.  
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To account for the energetic influence of impurities on the free energy change of 
heterogeneous nucleation a ‘wetting’ function,     , needs to be taken into consideration . 
The wetting function is dependent on the wetting angle,  , as shown in Figure 2.12.  
 
 
Figure 2.12|  Heterogeneous nucleation of a liquid droplet (with radius of curvature  , and projected 
radius      ) on a smooth structureless substrate, where   is the wetting angle which characterises 
the influence of the substrate. The Young equation
96
 is used to determine the wetting angle using 
the surface specific energies of the free surfaces of the substrate and droplet, and the interface 
between the droplet and substrate, denoted by      and  , respectively. Wetting angle, θ, on which 
The wetting function      is dependent on the wetting angle,  . Adapted from Markov95. 
 
Taking the wetting function,      into consideration the Gibbs free energy change 
associated with heterogeneous nucleation can be described by Equation 2.16. 
 
             
 
           (2. 16) 
 
For the case when        equals zero, known as complete wetting, the Gibbs 
free energy change,        equals zero indicating that it is thermodynamically unfavourable 
for heterogeneous nucleation to occur. A polar case to this would be complete non-wetting 
in which        equals one and          equals   
 
    . For this case, the critical nuclei 
formed are spherical and the impurities present in the sample do not have an energetic 
influence on the Gibbs free energy change for formation95. 
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2.3.4|  Chemical Crystallisation 
 
Chemical crystallisation is typically concerned with the crystallisation of relatively small 
compounds and peptides composed of less than twenty-four amino acids. This branch of 
crystallography is of significant importance due to the large spectrum of applications to 
which such molecules may be applied. For example, the structure solution of 
Cyclolinopeptide A, a nine residue cyclopeptide extracted from linseed oil97-99, has 
encouraged continued research exploring the cyclopeptide’s function as a potential 
immunosuppressor100. Successful, published structure solutions are submitted to the 
Cambridge Structural Database (CSD), the world repository of small molecule crystal 
structures which performs vital checks to ensure correct structures are published101.  
Solution methods are versatile and present a vast array of potential solvents, alone 
or in combination, which can be used to create a supersaturated solution of the given 
compound. There exist several variants of the solution method, including simple 
evaporation of the solvent, re-crystallisation by liquid diffusion and crystallisation through 
vapour diffusion in a closed system90 (Figure 2.13). The variant which yields the best crystals 
is entirely dependent on the compound under study. The compound’s solubility, thermal 
stability and chemical properties will all influence the choice of method and choice of 
solvent.  
 
Figure 2.13|  Methods of chemical crystallisation. a) Evaporation of solvent in an open system b) 
liquid diffusion in a closed system c) Vapour diffusion in a closed system. Dark grey indicates anti-
solvent and light grey indicates crystallisable material in solution. Adapted from Jones
90
. 
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2.3.5|  Protein Crystallisation 
 
Advances in molecular biology such as recombinant DNA technology had a profound effect 
on protein crystallisation. The development of various expression systems facilitated the 
production of large amounts of pure protein, a feat that could rarely be achieved using 
natural sources102. More recently, the biotechnology group within The Structural Genomics 
Consortium (SGC)103 have worked on determining which proteins can be expressed in a 
soluble and stable form which can be used for structural and functional studies. The group 
have continued the successful development and optimisation of high-throughput protocols 
for protein production and validation. Such advances have led to what is known as the 
‘bottleneck of crystallisation’, an increasingly acute problem1, and has seen the rapid 
development of protein crystallisation techniques within both industry and the academic 
community2 .  
 Substantial commitment has been put into developing rapid automation of protein 
crystallisation techniques to allow extensive screening of crystallisation conditions. Robots 
have now been successfully implemented and are routinely used within laboratories to 
great effect and efficiency104, 105. The structural information that can be gained from X-ray 
crystallography is extremely valuable, promoting the need for successful crystallisation 
techniques. For example, through X-ray crystallography, insight has been gained into the 
structure and mechanism of the ribosome, a key cellular organelle that enables the 
synthesis of proteins in all kingdoms of life. The structure of the Eukaryotic ribosome has 
successfully been solved to 3.0 Å by X-ray crystallography using crystals grown from hanging 
drop vapour diffusion crystallisation trays106, a commonly used technique detailed in Section 
2.3.6. The work achieved through X-ray crystallography is vast and is enabled both by 
advances in X-ray diffraction experiments and the development of successful crystallisation 
techniques, several of which are detailed in this following section. The success of this 
extremely valuable technique was celebrated through the Nobel Prize in Chemistry 2012, 
jointly awarded to Robert J. Lefkowitz and Brian K. Kobilka in107 “for studies on G-protein-
coupled-receptors”.  
 
2.3.6|  Vapour Diffusion Methods 
 
For protein crystallisation, the most frequently and successfully used crystallisation 
technique is that of vapour diffusion which includes the hanging drop, sitting drop and 
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sandwich variants (Figure 2.14). While hanging drop and sandwich vapour diffusion are 
manual methods, sitting drop vapour diffusion has efficiently been automated allowing 
beneficial rapid screening of crystallisation conditions. All variants consist of a reservoir 
solution containing precipitants and a crystallisation drop containing the protein and buffer 
solution. Water diffuses down its concentration gradient from the crystallisation drop to the 
reservoir solution bringing the crystallisation drop into supersaturation. This facilitates 
nucleation and subsequent crystal growth. Vapour diffusion set ups allow screening of many 
crystallisation conditions; an experimental necessity, as in most samples crystallisation will 
not occur due to incorrect external parameters such as, pH and type of precipitant (anti-
solvent). 
Figure 2.14|  Three vapour diffusion setups for protein crystallisation. a) Hanging drop b) Sitting drop 
c) sandwich drop. Light grey indicates the protein solution and dark grey indicates the reservoir 
solution. 
 
 Sandwich vapour diffusion is a rarely used variant of the vapour diffusion technique. 
However, the method facilitates the ability to reduce the area of a drop that is exposed to 
air, resulting in a slower rate of diffusion between the reservoir solution and the 
crystallisation drop compared to the rate observed for hanging and sitting drop setups.  
 Crystallisation (phase) diagrams (Figure 2.15) can conveniently be used to 
schematically visualise the events that occur during a vapour diffusion experiment. If 
nucleation does not occur early on in the metastable supersaturation region where 
spontaneous nucleation can take place, numerous critical nuclei may form resulting in 
potential growth of several small crystals (Pathway A in Figure 2.15). This is not ideal, and 
conditions which facilitate nucleation early in the spontaneous nucleation region should be 
found to allow ideally a single nucleation event resulting in the growth of a large single 
crystal (Pathway B in Figure 2.15) which may be suitable for X-ray diffraction experiments. 
Upon the formation of critical nuclei, crystal growth may occur until the crystals reach 
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equilibrium with the saturated solution, at which point (Point X in Figure 2.15) crystal 
growth does not continue. 
 
 
Figure 2.15|  Crystallisation phase diagram. Pathway A: An ideal situation in which nucleation occurs 
early on in the supersaturated metastable region resulting in a singular nucleation event and 
subsequent growth of a large single crystal. Pathway B: nucleation occurs further into the 
supersaturated metastable region resulting in numerous small crystals. X indicates the point at which 
the growing crystals reach equilibrium with the saturated solution, thus no more crystal growth 
occurs. 
 
In both hanging drop and sitting drop vapour diffusion, crystals may not form as a 
result of the closed system not reaching supersaturation, making it thermodynamically 
impossible for crystals to form. This negative result may be rectified by increasing the 
precipitant concentration of the reservoir solution108. Another plausible problem may be 
inadequate nucleation events due to a large kinetic barrier; this is potentially solved through 
seeding, which is the introduction of external nucleation points.  
 A clear advantage of sitting drop vapour diffusion compared to hanging drop vapour 
diffusion is the ability to automate the setting up of trays. Trays of 96 wells can rapidly be 
made with widespread crystallisation conditions; automatic dispensing robots have enabled 
the drop size to be reduced from typically 1 µl in manual setups to 100 nl, facilitating an 
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order of magnitude more experiments to be made with the same amount of valuable 
compound available. However, sitting drop trays are sealed with a sheet of adhesive tape 
which does not allow easy and repeatable access to crystals. Comparatively, for hanging 
drop trays, each well is covered by a siliconised glass cover slip which allows easy access to 
crystals, one well at a time, and enables the system to be resealed easily.  
 
2.3.7|  Batch Methods 
 
In contrast to vapour diffusion, the batch crystallisation set up involves the reservoir 
solution and the crystallisation solution being in direct contact with one another (Figure 
2.16) as opposed to separation through a gaseous phase.  
 
Figure 2.16|  Experimental setup for protein crystallisation using the batch method; the system is 
isolated and undisturbed to allow equilibrium to be reached. The drop (pale grey), a mixture of the 
protein and reservoir solutions is isolated from the environment via oil (dark grey). 
 
Conveniently, the batch method can be readily automated and miniaturised using nanolitre 
drops and immediate sealing of the system using oil. This microbatch method109 is efficient 
for the initial screening of crystallisation conditions and has successfully been 
implemented110, 111.  
 
2.3.8|  Polymorphism 
 
Polymorphism is a phenomenon whereby a particular compound in a solid crystalline state 
exists in two or more different lattice structures. Different crystal forms may be observed by 
varying crystallisation conditions and it can be advantageous to optimise these conditions to 
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obtain good quality crystals of numerous morphologies for a particular compound under 
study. Advantages include the ability to select a crystal morphology that gives the highest 
quality X-ray diffraction data. Also, information regarding crystallisation artefacts may be 
gained by studying several morphologies. 
 While advantageous in some respects polymorphism can be problematic within the 
pharmaceutical industry as great efforts are required to control polymorphism of 
Pharmaceutical active ingredients (APIs). Ostwald’s rule of stages11 states that the least 
stable (the metastable) polymorph tends to crystallise first, as this involves the 
crystallisation system moving to a lower energy via the smallest possible free energy 
change. This is the most likely result due to the typical kinetic control of crystallisation 
rather than thermodynamic control. Upon crystallisation of the metastable polymorph, it 
may then transform to a more thermodynamically stable form over a variable time period. 
APIs can display different crystal forms and morphologies which present varying 
bioavailability, absorption and release. Consequently, the pharmaceutical industry must 
ensure that a particular morphology of a particular API is obtained and that there is no 
question as to whether the polymorph obtained will transform over time.  Approval of the 
API will not be granted if this is not the case.  
 
2.3.9|  The Microemulsion Method: Thermodynamic Control of Crystallisation 
 
The favoured crystallisation of a metastable crystal form compared to a more stable form 
according to Ostwald’s rule of stages can be visualised using a free energy profile (Figure 
2.17). As discussed in Section 2.3.1, for crystal growth to occur there has to be sufficient 
energy to overcome a free energy barrier of nucleation, resulting in the formation of critical 
nuclei of radius   , thus permitting crystal growth. Figure 2.17a displays a Helmholtz free 
energy profile for conventional, unconfined crystallisation conditions. Under such 
conditions, the nucleation barrier for the metastable polymorph, B, is smaller than that for 
the more stable polymorph, A, and consequently the metastable polymorph will crystallise 
first, displaying kinetic control of crystallisation.  
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Figure 2.17|  Example graphs of Helmholtz free energy changes,    vs nucleus radius,  , for systems 
crystallising from a) bulk solution and b), c), d), a 3D nano-confined microemulsion solution. 
Polymorph A is the more thermodynamically stable, and polymorph B is metastable. (a) Ostwald’s 
rule of stages is observed. (b) Crystallisation is disfavoured and a minimum in free energy is formed 
due to 3D nano-confinement. (c) Thermodynamic control of crystallisation is achieved. (d) 
Thermodynamic control is lost and both polymorphs will typically crystallise out. Adapted from 
Cooper et al
3
. 
 
Microemulsions give the ability to ‘leap-frog’ Ostwald’s rule of stages and provide 
an elegant method of thermodynamically controlling crystallisation through three 
dimensional (3D) nano-confinement to directly crystallise the most stable polymorph. When 
a solution is three dimensionally nano-confined, a minimum in free energy is observed as a 
result of the substantial decrease in supersaturation as the crystal nuclei/phase forms and 
increases in size.  This minimum in free energy is denoted          , and the corresponding 
nuclei has a radius of        . Typically the minimum in free energy for the more stable 
polymorph, A, is less than that of the metastable polymorph, B, (          
 
    ). This 
difference in free energy is depicted in Figure 2.17b and can be expected as a result of 
polymorph A’s greater stability in solution. Before supersaturation is depleted polymorph A 
is able to grow to a larger size, with a greater radius (      ), compared to the metastable 
polymorph, B. This is because the stable polymorph has a lower solubility in solution.  
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 The Boltzmann Factor,                  , determines the population of nuclei of 
radius         when the system is at equilibrium and stipulates that a significant population 
of stable nuclei results when            . Subsequently, as schematically illustrated in 
Figure 2.17c, thermodynamic control can be established in 3D nano-confined 
microemulsions when             for the most stable polymorph, A, only. This condition 
would result in a significant population of post-critical nuclei for polymorph A given that the 
nucleation barrier for formation could be overcome. With smaller droplets within a 
microemulsion, higher initial supersaturations are reached ensuring that nucleation barriers 
can be overcome.  
The continued increase of supersaturation within a confined droplet has two 
possible outcomes: the retention of thermodynamic control or the system converting to 
kinetic control with the loss of advantageous thermodynamic control. The outcome is 
dependent on the relative proportions of        and  
 
     which results in favouring 
crystallisation of one polymorph over another. The equilibrium concentration of         can 
be maintained if the reverse process of         dissolution is of a sufficient rate. This would 
result in thermodynamic control being retained and is dependent on the magnitude of 
       
 
    . The rate of dissolution of  
 
      nuclei will be slow if   
 
    
 
      
   and the nucleation barrier,     , can be overcome. This is shown in Figure 2.17d where 
         . In this case the relative proportion of  
 
     and  
 
     then becomes 
dependent on their rates of formation only, and the system reverts to kinetic control as 
would be found in a non-confined bulk system.  
 Upon establishing thermodynamic control within the 3D nano-confined 
microemulsion and the subsequent formation of a significant population of stable nuclei of 
the most stable polymorph, crystal growth follows. Brownian motion describes the 
movement of microemulsion droplets and the potential for collisions to occur between 
droplets. If sufficient in energy, droplet collisions can result in the formation of transient 
dimers (Figure 2.18) which allow the exchange of material between droplets. The solute 
confined within the droplets will move according to its concentration gradient; a droplet 
containing one or several nuclei will have a lower local concentration surrounding the 
mentioned nuclei compared to a droplet in which no nuclei were established. Once crystal 
growth exceeds the limited size of the droplet the microemulsion will break and the crystal 
will precipitate out of the system and often settle at the bottom of the reaction vessel.  
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Figure 2.18|  Formation of transient dimers and subsequent exchange of material between droplets 
upon collision of microemulsion droplets. 
 
Microemulsions have successfully been used to implement thermodynamic control 
over the crystallisation of Glycine4. Glycine was an ideal small molecule to use as it can 
crystallise in three different polymorphic forms, with the most thermodynamically stable   
polymorph being just 0.2 kJmol-1 more stable at ambient temperatures than the metastable 
  polymorph112. Using microemulsion crystals of the most thermodynamic, γ polymorph 
were directly grown in ambient conditions. 
 
2.3.10|  Lysozyme: A Model Protein for Crystallisation Studies 
 
Lysozyme was the first enzyme structure to be solved by X-ray crystallography. It was first 
found in nasal mucus and named by Fleming in 1922113 when he observed the protein’s 
antibacterial properties. Known as a glycoside hydrolase enzyme, Lysozyme presents 
antibacterial properties through catalysing the hydrolysis of 1,4-beta-glycosidic bonds 
between N-acetylmuramic acid and N-acetry-D-glucosamine residues of peptidoglycan, a 
protective layer found on the cell walls of gram positive bacteria114-116. The main source of 
Lysozyme for research purposes is from hen egg-white (HEWL) but Lysozyme can also be 
found in animal tissues and fluids117. 
Since its discovery, Lysozyme has undergone extensive investigations118 and has 
been used to establish models for protein crystal growth and investigate some general 
crystalline properties of proteins119-121.  Lysozyme is commonly used as a model system due 
to its stability, solubility and ability to crystallise under different conditions122 yielding 
different polymorphic crystals.  Variation of additives, ions, pH and temperature have lead 
to the formation of six different symmetries of Lysozyme crystals123 tetragonal, monoclinic, 
triclinic, orthorhombic, hexagonal and trigonal. Appendix A1 summarises the varying 
crystallisation conditions that have been successfully used to grow different crystal forms of 
Lysozyme to yield structural information for the protein. 
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The first crystal structure of Lysozyme to be solved was a tetragonal crystal of Hen-
egg-white-Lysozyme (HEWL)124. Crystal structures of different crystal polymorphic forms 
rapidly followed including triclinic118, 122, monoclinic122, 125-127, orthorhombic118, 128 and 
hexagonal13, 128. Crystal structures for turkey egg-white Lysozyme (TEWL)129, 130 and guinea 
fowl egg-white Lysozyme (GEWL)131 have also been solved from hexagonal crystal forms. 
 
2.3.11|  Membrane proteins: A Crystallisation Challenge 
 
Crystallisation of aqueous soluble proteins is a time consuming process involving extensive 
trial and error in order to obtain well ordered three-dimensional crystals, a prerequisite to 
high resolution X-ray structural determination. However, membrane proteins, which 
traverse hydrophobic cellular membranes, present a further crystallisation challenge and 
typically prove to be more problematic due to the difficulty associated with their isolation 
and purification, a consequence of their hydrophobic nature. 
Domains of membrane proteins that display on the cell surface provide a large 
target for pharmaceuticals facilitating the potential therapeutic control of cell signal 
pathways. Aided by the three dimensional structure of membrane proteins, the structural 
based design of small molecules becomes an attainable goal. Industry values the potential 
held within membrane protein structure determination and requires a series of protein 
structures rather than a single result, in order to screen their pharmaceuticals as potential 
therapeutics. For this to be a reality, there is need for a reliable way of producing crystals of 
membrane proteins that diffract at a high resolution132.  
Membrane proteins are abundant in nature. Genome-wide analysis has predicted 
that 20-30% of the open reading frames from eubacterial, archaean and eukaryotic 
organisms encode for the production of integral membrane proteins133. In humans, 15-39% 
of the 23000 or so human proteins are thought to be integral membrane proteins. 
However, despite their abundance, there is a disproportionately low number of membrane 
protein structures submitted to the Protein Data Bank (PDB)134; of approximately 300 
integral membrane proteins, about twenty or so are human. This clearly reflects the 
difficulty in obtaining and crystallising membrane proteins.  
 This difficulty in crystallising membrane proteins results from the hydrophobic 
nature of the integral membrane domains which, when embedded in the cell membrane, 
are in contact with the hydrophobic acyl chains of the phospholipids. In comparison, 
soluble domains of membrane proteins are in contact with the surrounding aqueous phase 
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and the polar head groups of the phospholipids. When removed from the hydrophobic 
membrane environment into an aqueous solution, integral domains of membrane proteins 
become unstable and typically aggregate and precipitate out of solution. Amphiphilic 
detergents are therefore often required to solubilise membrane proteins in aqueous 
solutions. When the detergent is used above its CMC, a detergent micelle is established 
covering the hydrophobic surface of the membrane and providing stability for the 
membrane protein in an aqueous environment135-137.  
Currently, detergent based techniques remain the method of choice giving rise to 
the most success in the crystallisation of membrane proteins138. The protocol resembles 
that used to crystallise aqueous soluble proteins, in which detergent solubilised and 
purified membrane proteins are crystallised using standard vapour diffusion protocols. 
However, despite numerous examples of success, the quality of crystals gained from 
detergent based methods can be difficult to maintain, and in some cases require frustrating 
and time consuming crystal treatment in order to obtain a crystal of appropriate quality for 
structural determination139. It is therefore with good reason that time and resources have 
to be committed to explore alternative methods for the crystallisation of membrane 
proteins. Progress has been made through the use of protein specific antibodies which 
enable the enlargement of soluble domains to provide larger surface contacts for crystal 
formation140. This methodology has enabled crystallisation141 and structure solution142 of 
membrane proteins as complexes with anti-body fragments, but presents specialised 
protocols that may restrict access to the technique in many laboratories. An alternative to 
using protein specific antibodies to increase the soluble domains of membrane proteins is 
provided by protein engineering143. 
Lipidic phases offer an increasingly popular and promising methodology for 
membrane protein crystallisation. First demonstrated by Landau and Rosenbusch144, it was 
thought that by reintroducing purified membrane proteins into a lipid bilayer environment 
there would be an enhancement in the protein’s stability, which would support the 
crystallisation process. Three mesophases, lipid cubic phases (LCP), lipid sponge phases 
(LSP) and lipid bicelles, are method variants that branch from this central hypothesis. The 
characteristics of both LCP145 and LSP146  have been clearly established and, with the aid of 
small-angle X-ray scattering and cross-polarised microscopy, different lipid phases can 
easily be distinguished. Lipid bicelles can be thought as solubilised lipid bilayer disks147, 148 
that successfully maintain the functionality of reconstituted membrane proteins149. A 
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hypothesis has been proposed regarding how in meso crystallisation takes place at the 
molecule level150-152. 
 Lipid phases were first successfully used in 1997, permitting the structure 
determination of bacteriorhodopsin to 2.5 Å153; however, the crystals used were later found 
to be twinned154. A twinned crystal contains two or more single crystals of the same crystal 
lattice type but they lie in different directions resulting in some overlap between the 
respective crystal lattice points. Continuing from this initial success, the in meso method 
has enabled the crystallisation of both eukaryotic and prokaryotic membrane proteins, 
including chromophore-containing and chromophore-free proteins, multimeric proteins 
and α-helical and β-barrel proteins155. This highlights the method’s potential as a general 
protocol for the crystallisation of membrane proteins. The understanding of how 
membrane proteins function at a molecular level has been furthered by the use of lipid 
phases to crystallise membrane proteins for structural determination. For example, the 
structure of a sensory rhodopsin II-transducer complex revealed critical details into the 
modes of signal communication that takes place in phototaxis and chemitaxis156. Similarly, 
in 2007, the first high resolution structures of two non-rhodopsin G-protein coupled 
receptors (GPCR) were achieved using crystals grown from lipid phases157, 158.  
 The importance of further developing techniques for the crystallisation of 
membrane proteins is emphasised by the financial support given to the pursuit of 
membrane protein structure determination. In 2011, the Structural Genomics Consortium 
(SGC) received nearly £32 million from funding bodies, including the Wellcome Trust, to 
sustain four years of operations following their success in solving the structure of a human 
mitochondrial ABC transporter159, 160.   
 
2.4|  X-ray Crystallography 
X-ray crystallography is the most powerful tool for accurately determining the three 
dimensional structure of a compound. The diffraction pattern which forms as a result of a 
crystal being exposed to X-ray radiation enables the structure of a compound to be 
determined. This valuable technique can be used on a wide range of compounds, from small 
molecules to macromolecular proteins. 
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2.4.1|  Crystal Structure 
In 1611, Johannes Kepler was the first to explore the relationship between the regular 
external morphology of a crystal and the crystal’s internal order161. This lead to the 
development of a central concept in crystallography describing the composition of a crystal 
in terms of building blocks termed unit cells. A crystal can be generally described as a self-
assembled, periodic array of identical unit cells which are displaced repeatedly in three 
dimensions with translational and orientational long-range order. A unit cell (Figure 2.19) is 
described by three axial lengths, a,b,c and three angles, α, β, γ where α lies between axes b 
and c. Axial lengths are expressed in terms of Ångströms (Å), and the inter-axial angles are 
expressed in terms of degrees  (°) in most published papers. 
Figure 2.19|  A schematic depiction of a unit cell showing the three angles (α, β, γ) and three axes (a, 
b and c). 
The contents of a unit cell vary depending on the internal symmetry of the crystal ranging 
from a fraction of a molecule to one or more molecules. Some unit cells may even 
encompass a whole protein or large multi-component complexes. Unit cell geometries can 
be described using the seven crystal systems which result from restrictions in both 
rotational and reflectional symmetry. For structures which display more than purely 
translational symmetry, it is conventional to include more than one point in the unit cell so 
that the unit cell can better describe its symmetry. As a result, there exists what are known 
as the 14 Bravias lattices which each belong to one of the 7 crystal systems. It is the unit 
cells of the Bravais lattices which can be regarded as the “building blocks” of crystals. The 
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internal symmetry of a crystal is restricted as it must obey the translational symmetry of the 
crystal; consequently, 32 point groups and 230 crystallographic space groups are generated 
that can be used to describe the symmetry of a crystal.  
Protein molecules lack symmetry due being built from L-α-amino acids, resulting in 
their chiral nature. This limits the possible combinations of symmetry operations; all mirror 
symmetry operations are eliminated, generating only 65 discrete chiral space groups from 
which a protein crystal can be described.  
 
2.4.2|  The Reciprocal Lattice 
 
Mathematical constructs are required to aid the description of a crystal in relation to the 
diffraction events that emanate from it when exposed to X-rays. Developed by P. Ewald in 
1921162, the reciprocal lattice is one such mathematical construct which also enables the 
determination of the conditions necessary for diffraction to occur. To construct the 
reciprocal lattice, the crystal lattice in real 3D-space first has to be considered. The crystal 
lattice is dependent on the crystal’s unit cells geometry, as it is generated by representing 
each unit cell with an isolated point, with each lattice point being in exactly the same 
environment. Consequently, if the unit cell is large, a widely spaced crystal lattice would be 
generated. The reciprocal lattice is seen in the pattern of the diffracted spots and has a 
reciprocal relationship with the real 3D-space crystal lattice generated from the unit cell of 
the crystal.  
 
2.4.3|  Miller Indices 
 
Lattice planes, both in 2D (Figure 2.20a) and 3D (Figure 2.20b), can be drawn using lines 
through the points of the real 3D-space crystal lattice. There are multiple ways of classifying 
lattice planes. However, some are not ideally suited to aid the description of X-ray 
diffraction experiments. For example, the generation of Weiss indices for each set of lattice 
planes using a direct indexing scheme proves problematic, as planes that are parallel to a 
lattice vector intersect the corresponding lattice vector an infinite number of times which is 
mathematically unhelpful. Consequently, it is most beneficial to use reciprocal Miller indices 
to uniquely classify sets of lattice planes within the crystal.  
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Figure 2.20|  Regularly arranged crystal lattice points of  a) 2D lattice planes b) 3D lattice planes. 
 
 Miller indices         are always integers and are generated by selecting axes that 
facilitate the alignment of the axes x, y, and z with the unit cell axes a, b, and c respectively. 
Using the Miller Indices, planes can be defined by      ,      and      as shown in Figure 
2.21.  
 
Figure 2.21|  Miller Indices; here the Miller plane intersects the x axis at zero, the y axis at zero and 
the z axis at ¼. The plane is therefore defined as 004. 
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2.4.4|  X-ray Scattering 
  
X-rays are a form of electromagnetic radiation that interacts with matter mainly though 
their oscillating electric field vectors. A fundamental tool to understand X-ray diffraction 
experiments is the ability to geometrically describe the scattering events that take place 
when X-rays are scattered by electrons in the regularly arranged and orientated atoms 
present in the crystal. This can efficiently be achieved using scattering diagrams (Figure 
2.22), which describe scattering using wave vectors. The difference between the initial 
incoming wave vector,   , and the wave vector of the scattered wave,   , gives the 
scattering vector,  . Only coherent scattering (also known as elastic scattering) is relevant to 
the diffraction of X-rays. This is when a scattering event takes place without a transfer of 
energy between the electron and the photon. As a result of coherent scattering, all excited 
electrons emit photons which are in-phase. The diffraction pattern results from the sum of 
all independent, in-phase scattered photons.  
 
Figure 2.22|  Scattering diagram used to geometrically describe the scattering events that take place 
when X-rays are scattered by electrons in the regularly arranged and orientated atoms present in the 
crystal. 
 
 To simplify the interpretation of X-ray diffraction, Bragg’s Law can be applied. This 
central concept to X-ray crystallography, developed by Sir William Laurence Bragg, views the 
scattering vector,  , as a normal to the reflection of X-rays from a set of equidistant lattice 
planes a.  
 
                    (2. 17) 
 
This allowed the formulation of Bragg’s equation (Equation 2.17), which forms a 
quantitative relationship between the spacing between lattice planes,     , and the 
diffraction angle,  , of separate reflections. Consequently, it can be seen that for maximum 
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constructive interference, the path difference between two diffracted waves,       , has 
to be a multiple of   . 
 
Figure  2.23| Bragg’s law viewing X-ray diffraction as reflections from equivalent crystal lattice 
planes. 
 
2.4.5|  The Phase Problem 
 
Information regarding the phase of the waves emanating from excited electrons is required 
in order to determine the electron density, and hence crystal structure, from the diffraction 
pattern. However, the attainment of such information is the central problems presented by 
X-ray crystallography as only the intensity, equal to the square magnitude of the diffracted 
wave amplitude, is recorded and all phase information is systematically lost. The extraction 
of phase information is termed the phase problem. Herbert A. Hauptman and Jerome Karle 
were awarded the 1985 Nobel Prize in Chemistry for their work on direct methods used to 
help solve the phase problem; this clearly indicates the importance and significance of the 
phase problem in the determination of crystal structures. 
 The structure factor          for a reflection         is a complex number defined by 
Equation 2.18 and is calculated by summing over all atoms,  .  
 
                      
                      
     
     (2. 18) 
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The type of atom and the diffraction angle of the associated reflection         influences 
the scattering factor of an atom,     . From the positions of each reflection collected in a 
diffraction experiment, the indices         can be determined, and an appropriate intensity 
can be assigned to each reflection. The square of the structure factor amplitude can be 
determined experimentally, as it is proportional to the scalar intensity value. Subsequently, 
a Fourier Transform (FT) can be applied to the structure factor, which is a periodic function, 
to enable electron density to be evaluated and thus the structure determined. Equation 
2.19 describes the electron density resulting from the FT which enables an image in 
reciprocal space, the diffraction pattern, to be transformed into an image in real or direct 
space, the electron density. 
 
         
 
 
                   
                          (2. 19) 
 
 The phase problem prevents the immediate calculation of electron density as the 
structure factor is only known in part; phase information, which is not recorded, is still 
required. Several techniques have been developed with the aim of solving the phase 
problem. The first crystal structures were solved by trial and error163; however, this method 
had a very low efficiency, particularly for crystals of low symmetry. Alternative phase 
techniques include the Patterson method164, which was later developed and relies on 
additional experimental information gained through the use of heavy atoms within the 
structure. Today the more widely used direct methods approach165 is applied to solving the 
phase problem which was developed by Woolfson and Sheldrick into widely used programs. 
The methods above were developed for the structure solution of small molecules; other 
methods have been developed for solving the phase problem for protein crystals. 
 
2.4.6|  Small Angle X-ray Scattering (SAXS) 
 
Colloidal dimensions are comparatively large with respect to the wavelength of X-rays. This 
makes the angular range of observable X-ray scattering experiments comparatively small. 
Therefore, for solids and fluids of colloidal size (in the nanometre range), small angle X-ray 
scattering (SAXS) can be utilised to explore their structural characterisation through probing 
inhomogeneties in their electron densities on a length scale of typically 1-100 nm. SAXS 
enables the determination of size, shape and internal structure of colloidal particles, 
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measuring at angles less than 1°. This analytical technique typically only considers coherent 
scattering since incoherent scattering is weak at very small angles.  
  
       
  
 
        (2. 20) 
 
The data gained from SAXS experiments is commonly presented in scattering 
vectors of   (Equation 2.20), instead of    which is quoted in X-ray crystallography. This 
proves beneficial for obtaining results which are independent of the wavelength used. 
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Chapter Three 
Experimental Methods 
 
3.1|  Chemical Crystallisation 
 
All chemical compounds for crystallisation were provided by members of Dr Steven Cobb’s 
research group in the Department of Chemistry, Durham University. The compounds ASH89, 
ASH81/87, ASH93, ASH91, ASH82, ASH90 and ASH59 compounds were stored in the fridge 
at 4°C and GDL02, GDL38 and GDL39 compounds were stored at room temperature. None 
of the compounds were air sensitive; however, as a precaution compounds were stored in 
tape sealed glass vials. Appendix A2 details the preparation of each of the above mentioned 
compounds. 
 
3.1.1|  Initial Solubility Screens 
 
Prior to solubility screens, initial observations of the sample were made under an optical 
microscope and the nature of the sample was noted including the sample’s crystallinity (as 
shown through birefringence using a polarised light filter), colour and habit as well as the 
presence of any crystals from which a crystal shape could be predicted. A small amount of 
compound for study was spread in a central thin line over the length of a standard glass 
microscope slide and up to 6 µl of solvent was used. A range of solvents were used with a 
broad range of boiling points.  
 A clean needle was used to add a small amount of powdered compound to each 
solvent drop which was deposited onto the glass slide using a 2-20 µl Gilson pipette. The 
relative extent of the compound’s solubility in each solvent was visualised under the optical 
microscope and noted. Further observations were also made regarding the occurrence of 
any crystallisation upon evaporation of the solvent and the manner in which the powdered 
compound separated upon being added to the solvent. This could potentially indicate the 
shape of the crystalline material in the sample and may also suggest the habit that would 
result upon crystallisation of the compound.  
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3.1.2|  Crystallisation by Evaporation 
 
For solvent evaporation experiments it is preferable to use a watch glass, a nine-well glass 
plate or a glass vial. All glass must be free from dust and clean and have a means of easily 
removing small crystals. For example, the aperture of the glass vial must be of a large 
enough size for efficient crystal removal. When using solvents of a comparatively higher 
boiling point, such as Polyethylene Glycol (PEG), it may be suitable to carry out the 
evaporation experiment on the initial glass slide used for solubility screening. 
 It is often preferable to use a glass vial as these can be stored at a slight angle to 
promote crystal growth on the side of the vial rather than at the bottom of the vial, thus 
aiding collection of the crystals. Also, the rate of evaporation for volatile solvents can be 
more readily controlled through the use of a perforated cap. For slow evaporating solvents 
the vial can be left uncapped. Altering the temperature or the rate of evaporation may allow 
a stable and sustainable growth phase to occur. To explore this, in some cases, evaporation 
experiments were repeated in the refrigerator at 4°C. Lowering the temperature of 
evaporation experiments may prevent crystallisation failure by allowing molecules of the 
compound to orientate in identical conformations for a period adequate for sustaining 
crystal growth.  
Supersaturation of the system is achieved through the evaporation of the solvent. 
This allows nucleation to occur with the system relaxing into the metastable region and 
facilitating crystal growth. However, evaporation experiments are difficult to reproduce due 
to the many varying conditions that can influence an open system. Upon evaporation of the 
solvent no crystallisation may occur due to the system not reaching the point of 
supersaturation. This undesirable result can potentially be solved by varying the ratio of 
solvent and sample. However, with a limited amount of material (less than 5 mg) this 
methodology may waste material if the solvent is unsuitable. If this is the case, it is desirable 
to seek an alternative solvent in which the compound displays a lower solubility.   
 
3.1.3|  Crystallisation by Liquid Diffusion 
 
The open system of evaporation experiments may not result in crystallisation. Alternatively, 
a closed system may be more successful by enabling a higher degree of control over the 
conditions for crystallisation experiments. Crystallisation from evaporation experiments 
may fail as a result of the compound’s solubility being too high in the chosen solvent, 
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preventing supersaturation from being reached. Anti-solvents offer a solution to this 
problem and can be implemented using liquid diffusion experiments.  
 Solvents in which the sample is insoluble (or barely soluble) are by definition anti-
solvents. The anti-solvents for each sample can easily be identified using the initial solubility 
screen. By using solvents in combination with anti-solvents the sample’s solubility can be 
modified and supersaturation can be established within a closed system, making nucleation 
and crystal growth attainable.  
Ideally the solvent used should provide moderate solubility for the sample. 
However, if this is not available, a solvent in which the sample has a high degree of solubility 
has to be used and consequently a stronger anti-solvent is required. The solvent and anti-
solvent should be miscible but have distinct densities. This requirement facilitates the 
formation of a diffusion region, an area in which the solvent and anti-solvent are in contact 
but to a limited degree. An undesirable extent of mixing will occur if the two solvents have 
too similar densities. It is most helpful if the solvent with the dissolved sample has a higher 
density and volatility than the anti-solvent, allowing the anti-solvent to form the top layer 
within the glass vial. The system can be reversed but at the disadvantage of not being able 
to add more anti-solvent upon requirement.  
If liquid diffusion experiments do not yield any crystals, they can readily be altered 
in an attempt to improve the crystallisation conditions. More anti-solvent can be added to 
ensure supersaturation is attained and temperature can easily be varied. However, care 
must be taken to ensure as little disturbance to the system as possible in order to avoid 
over-mixing of the two solvents.  
 
3.1.4|  Crystallisation by Vapour Diffusion 
 
Vapour diffusion is a flexible technique suitable for small amounts of sample. Compared to 
liquid diffusion, vapour diffusion is a slower crystallisation technique which will aid the 
growth of more ordered, single crystals. If no crystallisation results, the glass vials 
containing the solvent/sample solution can easily be moved to a different anti-solvent, thus 
preventing sample from being wasted.  As with liquid diffusion, it is preferable for the 
sample/solvent solution to be less volatile than the anti-solvent; however, it is less 
problematic in vapour diffusion if this is not the case.  
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3.1.5|  Selecting and Harvesting a Crystal 
 
As briefly discussed in Section 2.3 there exist key indicators to aid selection of a suitable 
crystal for X-ray diffraction experiments. The shape of a crystal is the most immediate 
indicator of quality. Crystals with well defined edges and no ‘satellite’ crystals are preferred. 
‘Satellite’ crystals cannot be removed from the surface of crystals, and therefore present no 
potential use in single crystal X-ray diffraction experiments. Except for a few cases (cubic 
crystals and tetragonal and hexagonal crystals if viewed along the c axis), crystals are 
birefringent. A crystal which displays even birefringence across the whole crystal when 
rotated under polarised light is likely to be highly ordered and therefore of appropriate 
quality. Often the equipment being used for X-ray diffraction experiments may influence the 
size of crystal required to produce a good data set. It is only through screening potential 
crystals (Section 3.5.2) that the required size of a particular crystal can be inferred.  
 To harvest a selected crystal a paper taper is used to transfer the crystal from the 
crystal growth medium (mother liquor) to a small amount of inert oil placed on a glass slide. 
Care should be taken to ensure the crystal remains intact. It is advantageous to transfer a 
crystal to a drop of inert oil (Fomblin), as often this provides a more viscous medium which 
aids the manipulation of crystals and helps secure the crystal once it is mounted and frozen 
in the Cryo stream. In some cases crystals grow as clusters from which a fragment may be 
broken off to produce a single crystal which may potentially be suitable for X-ray diffraction 
experiment. Clusters can be teased apart or fragmented using a needle or a paper taper 
which is less likely to cause destructive damage. 
 To mount the crystal onto the X-ray diffractometer for screening (Section 3.5.2), a 
glass fibre attached to a pin is used. The pin is then attached to the goniometer head ready 
for screening the crystal. Before the crystal was collected onto the glass pin the pin was 
approximately centred on the diffractometer. Care was taken to ensure a minimal amount 
of fomblin oil was collected with the crystal. 
 
3.2|  Protein Crystallisation 
 
Surfactants and solvents were of a laboratory reagent grade (unless stated otherwise)  and 
were used as supplied: Span80 (Sigma), Brij30 (Sigma-Aldrich), Tween80 (Sigma-Aldrich), 
Aerosol-OT (AOT) (Fisher - general purpose grade), TritonX-100 (Fisher - Electrophoresis 
grade), TritonX-114 (Sigma-Aldrich), n-heptane (Fisher), cyclohexane (Fisher), 1-hexanol 
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(Sigma-Aldrich), sodium chloride (sigma  99.5%). Lysozyme from chicken egg white, 
provided by Sigma-Aldrich (Fluka), was used for crystallisation experiments. Water was 
obtained from a USF Elga Purelab water purifier and purified to a resistivity of 18 MΩcm.  
 
3.2.1|  Preparation of Hanging Drop Vapour Diffusion Trays 
 
Hanging drop vapour diffusion trays for Lysozyme crystallisation were set up as shown in 
Table 3.1. A protein solution of 50 mgml-1 Lysozyme in 0.1M NaAc pH 4.8 buffer was 
prepared and centrifuged using a desk-top centrifuge for three minutes to sediment any 
dust and/or non-dissolved Lysozyme. Stock reservoir solutions were prepared consisting of 
10% (w/V) NaCl, 0.1M NaAc buffer of varying pH (pH 4.4, 4.8, 5.2, 5.6) and 25% (V/V) 
ethylene glycol. A volume of 1 µl was used per drop and the wells were filled with 0.5 ml of 
reservoir solution. Each well was sealed using vacuum grease and a siliconised cover slip. 
Crystallisation trays were stored at room temperature.  
 
 
Ratio for Protein solution(µl):Reservoir 
solution(µl) 
3:1 2:1 3:2 2:2 1:2 1:3 
pH of Buffer 
solution 
Well reference 1 2 3 4 5 6 
4.4 A       
4.8 B       
5.2 C       
5.6 D       
 
Table 3.1|  Set up for 4x6 hanging drop vapour diffusion crystallisation tray. 
 
3.2.2|  Microemulsion Preparation  
 
To date, the crystallisation of proteins using microemulsions to produce single crystals of an 
appropriate quality for X-ray diffraction experiments has not been explored. Previous work 
involving proteins and microemulsions includes the use of w/o AOT microemulsions as a 
medium to control aggregation of Ferritin166, a water soluble, iron storage protein, in order 
to produce discrete protein nanocrystals. Also, microemulsions have successfully been used 
as a reaction medium for the immobilisation of proteins to hydrophilised surfaces167 and a 
means of separating protein mixtures168, 169.  
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3.2.2.1|  Phase Diagrams 
 
Conducted at room temperature, ternary phase diagrams (Figure 3.1) for different 
surfactant systems were made, varying the ratio (percentage by mass) of aqueous, oil and 
surfactant phases. 
 
Figure 3.1|  Ternary phase diagram used to select appropriate ratios of aqueous, oil and surfactant 
phases to give stable, transparent microemulsions. 
 
For systems in which a co-surfactant was used the ratio of the two surfactant components 
remained fixed. Assessment was conducted visually noting a colourless, transparent, non-
gel like solution to be a microemulsion. Table 3.2 gives the components used in each ternary 
phase diagram. 
 
Aqueous Phase Oil Phase Surfactant/co-surfactant 
H2O Cyclohexane TX-114 
H2O Cyclohexane TX-100:1-hexanol (1:1 w/w) 
5% (wt) NaCl by mass in H2O Cyclohexane TX-114 
5% (wt) NaCl by mass in H2O Cyclohexane TX-100:1-hexanol (1:1) 
0.1M NaAc pH 4.8 Heptane Span80:Tween80 (1:1) 
5% (wt) NaCl by mass is H2O Heptane AOT 
H2O Heptane AOT 
 
Table 3.2| Components of ternary phase diagrams. 
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3.2.2.2|  Ionic Surfactant Systems 
 
Test protein Lysozyme is an aqueous soluble, globular protein. Subsequently, to explore 
thermodynamic control of Lysozyme crystallisation via 3D nanoconfinement in 
microemulsions, water-in-oil microemulsions (Winsor II) are required. Following the 
successful application of microemulsions for Ferritin aggregation166, the use of AOT as a 
surfactant system provides a starting point for the application of microemulsions for 
Lysozyme crystallisation. 
Stock solutions of 10% (wt) and 5% (wt) of AOT in heptane were prepared and 
sonicated for one hour to ensure all AOT was dissolved and a homogenous solution was 
formed. To explore the amount of aqueous phase that could be confined within the 
surfactant/continuous phase and to serve as a control experiment, varying amounts of pure 
water (10-100 µl) was added to varying volumes of surfactant/continuous phase solution 
(0.5-5 ml). A ternary phase diagram was generated at room temperature to aid the 
determination of a suitable ratio of surfactant/continuous to aqueous phase. Upon addition 
of the aqueous phase to the surfactant/continuous phase the sample was shaken by hand 
or vortexed to facilitate the complete dispersion of the aqueous phase. In some cases were 
shaking and votexing appeared insufficient, the sample was placed in a sonicator bath set at 
room temperature to form, in successful cases, a transparent, single phase microemulsion. 
Moving forward, stock solutions of varying Lysozyme concentrations (5-50 mgml-1) 
were made using solvents of pure water and four different buffer solutions of 0.1 M NaAc 
with varying pH (4.6, 4.8, 5.2 and 5.6). Lysozyme solutions were stored in the fridge at 4°C 
and were not sonicated in order to prevent denaturing the protein by the potential localised 
increase in temperature170. Aliquots of Lysozyme solution were added to the 
surfactant/continuous phase, vortexed or sonicated, and then stored at room temperature. 
A series of experiments were conducted to explore the effects of varying the ratio of 
dispersed (aqueous) phase to surfactant/continuous phase, the concentration of Lysozyme 
and the aqueous buffer used. The same microemulsion preparation method was used for 
each surfactant system used as detailed in below sections. 
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3.2.2.3|  Non-ionic Surfactant Systems 
 
As previously mentioned, thermodynamic control of crystallisation has been successfully 
demonstrated with the crystallisation of glycine polymorphs4. This was achieved using a 
surfactant system of Span80:Brij30 in a 1:1 ratio dissolved in heptane to make a 40% (wt) 
surfactant solution. Subsequently both Span80:Brij30 and Span80:Tween80 surfactant 
systems were applied to Lysozyme crystallisation experiments. This would also enable a 
comparison to be drawn between non-ionic surfactant systems and ionic (AOT) surfactant 
systems in the use for Lysozyme crystallisation. 
Batch solutions of Span80:Brij30 in a 1:1 ratio 40% (wt) in heptane and 
Span80:Tween80 in a 1:1 ratio 20% (wt) in heptane were prepared and sonicated for two 
hours and left to settle for 24 hours to allow the homogeneous surfactant solution to return 
to room temperature. As with the AOT surfactant system, a phase diagram and a series of 
experiments were conducted to explore the affects of several variables including the ratio of 
dispersed (aqueous phase) to surfactant/continuous phase, the concentration of Lysozyme 
and the aqueous buffer. 
Further exploring the use of non-ionic surfactant systems, both TritonX-100 (TX-100 
and TritonX-114 (TX-114) were used. The TX-100 surfactant required the use of a co-
surfactant, 1-hexanol, in order to form stable w/o microemulsions. A 1:1 ratio of surfactant 
to co-surfactant was used for TX-100, and for both TX-100 and TX-114, cyclohexane was 
used as the continuous phase.  Appropriate ratios of water:surfactant/co-surfactant:oil 
were noted from the phase diagrams and samples of these ratios were made in which the 
water was replaced by a solution of Lysozyme in water of varying concentrations for both 
TX-100 and TX-114 . 
 
3.2.2.4|  Methods for Further Facilitating Crystallisation in Microemulsions 
 
As with other crystallisation methods, it is sometimes found that addition of an anti-solvent, 
also known as a precipitant, is required to bring the solution into supersaturation to enable 
nucleation and subsequent crystal growth. To apply this to the microemulsion method, 
several approaches were employed using solutions of sodium chloride (NaCl) as the anti-
solvent.  
 The direct addition of bulk solutions was used to first establish an approximate ratio 
of protein to anti-solvent solutions that would bring the protein concentration into 
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supersaturation and facilitate crystal growth as detailed in Table 3.3. The ratio was then 
applied to microemulsions by directly adding an aliquot of anti-solvent solution directly to 
the microemulsion and mixing the two together via vortexing.  
 
 
[NaCl]   
(% wt) 
500 µl 
Lysozyme 
50 mgml-1 
in water 
500 µl 
Lysozyme 
50 mgml-1 
in water 
500 µl 
Lysozyme 
50 mgml-1 
in 0.1M 
NaAc pH 4.8 
500 µl 
Lysozyme 50 
mgml-1 in 
0.1M NaAc 
pH 4.8 
Volume of 
NaCl solution  
(µl) 
5 500 1000 500 1000 
10 500 1000 500 1000 
15 500 1000 500 1000 
20 500 1000 500 1000 
 
Table 3.3|  Direct addition of anti-solvent solution (NaCl solution) to bulk Lysozyme solution of 
concentration 50 mgml
-1
. 
 
 An alternative, mixed microemulsion method was also used in an attempt to 
introduce anti-solvent into the system. Mixed microemulsions have previously been used in 
the crystallisation of glycine in which methanol was used as the anti-solvent4. Phase 
diagrams incorporating different concentrations of an anti-solvent solution as the dispersed 
aqueous phase were established for each surfactant system. Both Lysozyme microemulsions 
and anti-solvent microemulsions were separately made then directly mixed together and 
vortexed. Again, the ratio of Lysozyme solution to anti-solvent solution was applied to the 
mixed microemulsion method where possible. In some cases, ratios of the three 
microemulsions components for the anti-solvent system that lay just outside the region in 
which a microemulsion was formed were also used. This explored the possibility that the 
mixing of a Lysozyme microemulsion with an anti-solvent emulsion or nano-emulsion may 
form a microemulsion overall.  
 In the absence of anti-solvent, a method in which the continuous phase was 
evaporated was used. The mass of the microemulsion was taken before and after the 
evaporation of continuous phase and the volume of the microemulsion was allowed to 
reduce by approximately two thirds, as judged by eye. Evaporation experiments were 
conducted in a fume hood 48 hours after the microemulsions had been made.  
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3.3|  Microemulsion Droplet Size Determination 
 
SAXS and subsequent GIFT analysis were used to confirm the formation of microemulsions 
in samples of each surfactant system by determining the droplet size. Sample that diffract 
and have droplet sizes within 1-100 nm are considered to be microemulsions.   
 
3.3.1|  Geometric Calculations 
 
An estimate of the microemulsion droplet radius can be made using geometrical 
calculations. When the composition of the microemulsions is known, Equation 3.1 can be 
used to predict the droplet radius, where   is the dispersed volume fraction,    is the 
number of surfactant molecules per unit volume and   is the area per surfactant molecule78. 
 
       
  
   
     (3. 1) 
 
Geometric calculations of microemulsion droplet radius assume that all the 
surfactant/co-surfactant molecules sit at the oil-water interface and that each of them 
occupies a well-defined area, independent of the microemulsion’s composition.  
 
3.3.2|  X-ray Scattering Experiments for Microemulsions: SAXS 
 
Small Angle X-ray Scattering (SAXS) can be used to determine the size of droplets within 
microemulsion samples experimentally, and confirm whether 3D nanoconfinement has 
been achieved. SAXS data was collected using a Brucker Nanostar SAXS machine operated at 
40 kV and 35 mA to produce Cu Kα radiation with a wavelength of 1.54 Å. The machine was 
fitted with a Hi-star 2D detector at a distance of 65 cm and had cross coupled Gobel mirrors 
and pinhole collimation for point focus geometry.  
 Microemulsion samples were inserted into the sample chamber via a sealed 2mm, 
vacuum tight quartz capillary and the chamber evacuated to a pressure of 10-1 mbar. It is 
important for the capillary to be positioned correctly at a point where minimal transmission 
occurs. The ideal positioning of the capillary can be ensured using the Gadds program 
Radiography/nanography run with the attenuator in the dropped position.  A data collection 
can be made once the sample stage has been set to the ideal position and the attenuator 
returned to the lifted position. The time taken to collect sufficient SAXS data can easily be 
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changed and depends on the nature of the sample.  The duration of the SAXS experiment 
should be modified in order to gain a good signal to noise ratio. For each surfactant system, 
SAXS data was collected for 2 hours.  
 
3.3.3|  Generalised Indirect Fourier Transform (GIFT) 
 
SAXS data collected from a dilute solution can be directly related to the scattering particles 
using an indirect Fourier transformation.  However, for more concentrated solutions, 
evaluation of SAXS data diverges away from a solution to a linear weighted least-squares 
problem. This is due to the resultant scattering intensity including both intra- and inter-
particle scattering contributions. Unlike dilute solutions, particle interactions have to be 
taken into consideration and it can no longer be assumed that the average distance 
between particles is much greater than the dimensions of the particles themselves171.  
Scattering from isolated particles, as found in dilute solutions, can be expressed by 
the form factor,       where   is the length of the scattering vector, which describes intra-
particle scattering. The structure factor,       corresponds to the inter-particle scattering. 
Under certain conditions, the product of the form factor and the structure factor can be 
used to approximate the total scattering intensity,      (Equation 3.2). In these cases 
evaluation of the scattering data becomes a non-linear problem171. 
 
                     (3. 2) 
 
For concentrated solutions, it is important not to neglect inter-particle interactions 
as the influence of the corresponding structure factor can readily be seen in the 
experimental data through the deviation of the scattering curve from the ideal particle 
scattering curve at low   values. Also, scattering intensity decreases at low   values due to 
repulsive interactions between particles. Oscillations in the pair distance distribution 
function may result from these deviations at low   values, leading to incorrect evaluation of 
the experimental scattering data.  
 The structure of aggregates in solution is dependent on the concentration of 
amphiphilic molecules. It is therefore not possible to eliminate the influence of inter-particle 
interactions by conducting SAXS experiments at several concentrations and then 
extrapolating the scattering data to a concentration of zero. Consequently, a global 
technique for the evaluation of SAXS data was developed that allows the simultaneous 
determination of the form factor and the structure factor through the use of an algorithm to 
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solve the non-linear least squares problem.  The technique developed, known as 
generalised indirect Fourier transformation (GIFT)171, is possible due to the different 
analytical behaviour of the two functions for the form and structure factors. GIFT does not 
use models or analytical restrictions for the determination of the form factor. However, the 
determination of the structure factor is parameterised. For a particular particle interaction 
model, up to four parameters (including volume fraction, polydispersity, radius and effective 
charge) can be utilised.  
 The pair distance distribution function,     , which can be obtained by the Fourier 
transform of the scattering curve, measures the probability, weighted by the electron 
density contrast, of finding a distance  , within the scattering particle. Hence       falls to 
zero at the largest dimension of the scattering particle. The scattering data will fit one of 
several models; the model can be inferred from the shape of the      function. For a core 
shell model, the      function will have minima corresponding to regions of electron 
density of alternating sign, often relating to differences in the electron densities of the inner 
phase, the surfactant and the continuous phase. The      function for the hard sphere 
model has no minima and results due to there being negligible difference in the electron 
densities of the surfactant tail groups and the continuous phase. If there is only a very slight 
difference between the electron densities of the surfactant tails and the continuous phase, 
the surfactant tails may not be effectively seen by SAXS due this difference being negligible 
and there may be partitioning of the oil continuous phase among the surfactant tails. 
GIFT analysis has been successfully applied to many cases including an investigation 
into various intrinsic parameters that influence structural variation of reverse micelles in 
non-ionic surfactant/oil systems172. Within the investigation detailed in this thesis, GIFT 
analysis is applied to determine the droplet size of reverse micelles to confirm the formation 
of microemulsions in systems used to attempt crystallisation of Lysozyme.  
   
3.4|  Optical Microscopy 
 
Optical microscopes enable the magnification of small objects using visible light and a lens 
system. Typically, this is an appropriate means of clearly viewing crystals which is aided by 
the use of filters to polarise light, highlighting the birefringent nature of crystals. Materials 
that appear birefringent which have a refractive index dependent on the polarisation and 
propagation direction of light. Optical microscopes were used to monitor crystal growth, aid 
initial solubility screens for small molecule crystallisation, harvest crystals for X-ray 
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diffraction experiments and to capture images of crystals. Both a Leica MZ16 and Leica 
M165C were used to do this.  
  
3.5|  X-ray Diffraction Experiments for Single Crystals: X-ray Crystallography 
 
Upon selection of a high quality single crystal, X-ray diffraction experiments were conducted 
as a means of further differentiating the quality of crystals grown using microemulsions. The 
quality of data obtained from crystals grown using microemulsions was compared to the 
quality of data sets collected from crystals grown using standard vapour diffusion methods.  
 
3.5.1|  Harvesting a Crystal 
 
Upon selection of potential crystal(s) (Section 3.1.5), taking into consideration the quality of 
crystal, a method for extracting the crystals from their growth environment has to be 
established. The method of extraction used depends on the type of experimental setup. 
Individual wells from hanging drop vapour diffusion trays can be independently selected; 
the cover slip can then be turned over and placed on a suitable stage (typically the lid of the 
hanging drop tray). The crystal(s) can then be directly harvested from the crystallisation 
drop. If more than one crystal is present in a drop, the cover slip can be returned to the 
hanging drop tray and the system resealed, ready for harvesting a crystal for a later 
experiment. Harvesting crystals grown via microemulsions required a less direct approach. 
Due to the depth of the glass vials which contained the microemulsions, crystals could not 
be independently and directly selected from the bottom of the glass vial. Aliquots of the 
microemulsion/crystal mixture were taken by gently drawing up a sample from the bottom 
of the glass vial using a Pasteur pipette to which the opening had been increased by 
breaking off the bottom glass part (care was taken to prevent contamination with glass 
shards/dust). The aliquots were then deposited on a glass slide from which crystals could be 
selected and directly harvested.  
 Crystals selected were then screened on a diffractometer. This required crystals 
grown from both hanging drop vapour diffusion trays and microemulsions to be harvested 
using a CryoLoop173. The size of the CryoLoop was selected to accommodate the size of the 
crystal. Typically a 0.4-0.5 mm CryoLoop was required. Care was taken to include a minimal 
amount of solution that surrounded the crystal when picking up the crystal in the CryoLoop. 
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Some liquid is required to secure the crystal once it has been frozen in the Cryo stream, 
however an excess should not be used to avoid interference with diffraction.  
 
3.5.2|  Screening a crystal 
 
Screening on the diffractometer174 can be used to indicate the diffraction quality of the 
crystals. This is required as, although in some cases a crystal appears of a good quality under 
the microscope it may diffract poorly and vice versa, a crystal which visually appears to be a 
poor quality crystal may in fact diffract well.  
 Before picking up the selected crystal, the head of the CryoLoop was roughly 
centred on the diffractometer using the attached camera. This ensured that once mounted 
onto the goniometer the crystal was likely to be directly in the Cryo stream and be in a good 
starting position for the crystal to be centred. Centring (Figure 3.2) the crystal required 
finding the crystal’s centre of gravity. This ensures the crystal remains in the path of the X-
ray beam at all times by preventing the crystal from slipping or becoming dislodged when 
rotated. To centre the crystal, small pins on the goniometer head were used to alter the 
position of the CryoLoop while rotating through φ at an Ω angle of 60°.  
 
Figure 3.2|  Centring a crystal, approximately 0.5 mm x 0.4 mm x 0.3 mm in size, is aided through use 
of the attached camera which gave rise to this image. 
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 To screen the crystals for diffraction quality single frames of widths 1° and 0.5° were 
taken at angles φ of 0° and 90°. An exposure time of 10 seconds was adequate for the 
testing of Lysozyme crystals grown from both hanging drop vapour diffusion trays and from 
microemulsions. Exposure times can be varied to give reflections of an appropriate intensity 
that do not exceed the limits of the detector. An idea of diffraction quality can be obtained 
from the diffraction image (Figure 3.3); ideally reflections are bright, have well defined 
edges and are not doubled as this would indicate that the crystal is not a single crystal. Data 
should not be collected from crystals that diffract poorly. 
 
Figure 3.3|  A diffraction image can give an initial idea of the quality of diffraction from a single 
crystal by considering the brightness and shape of the diffraction spots.  
 
 An orientation matrix was determined for the first crystals grown from a hanging 
drop vapour diffusion tray and from microemulsions that diffracted well enough to warrant 
collecting a data set from. This process enabled the unit cell of the crystals to be determined 
by determining the matrix function. The matrix function relates the real-space unit cell of 
the crystal to the reciprocal lattice.  
The determination of the crystal unit cell is an important piece of information to 
initially obtain. Through collecting sufficient data in order to determine the unit cell it is 
possible to infer the ability of the crystal to diffract well at a variety of φ and Ω angles and 
also the crystal’s ability to retain sharp and intense reflections as initially observed through 
the screening of the crystal.  For collection of data in the aim of solving the crystal structure, 
knowledge of the unit cell aids the design of the data collection in order to gain a data set 
which is complete. If there is doubt to the correct unit cell, data collection should be 
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designed assuming that the correct unit cell is the one with the lowest symmetry. This will 
reduce the possibility of collecting an incomplete data set which would have limited 
benefits.   
 
3.5.3|  Data collection and Processing 
 
A Brucker MicroStar diffractometer was used for the screening of crystals and for data 
collection of crystals grown from both hanging drop vapour diffusion and microemulsions. 
X-ray radiation was sourced from a copper rotating anode and the diffractometer was set 
up with a Helios mirror monochromator system and a Platinum 135 CCD area detector. The 
diffractometer was operated at 40 kV and 60 mA. 
 The same data collection strategy was used for all Lysozyme crystals consisting of a 
range of φ and Ω scans. An exposure time of 30 seconds was used. A manual design of the 
data collection strategy was sufficient to achieve a complete data set. However, if required, 
there is data collection strategy software which can be utilised to design a complete 
diffraction experiment with an appropriate redundancy. Redundancy is the term used to 
describe repeated collection of equivalent reflections. The software also gives an estimated 
time of completion taking into consideration the exposure time for each frame. 
 Upon completion of a data collection the data is merged, integrated and scaled 
using SAINT and automatic absorption corrections are made using SADABS. Following this 
initial processing, XPREP175 is used to examine the systematic absences in the reflection data 
and determine the space group of the crystal. For the Lysozyme crystals, data processing 
was not taken any further and statistical values were compiled for each data set.  
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Chapter Four 
Results 
 
4.1|  Chemical Crystallisation 
 
The following sections (Section 4.1.1 – 4.1.8) details the crystallisation results for 
compounds described in Appendix A2. The methods for the crystallisation of these 
compounds are discussed in Sections 3.1.1 – 3.1.4. 
 
4.1.1|  Crystallisation of ASH89 
 
The sample of ASH89 provided appeared birefringent under polarised light, was off-white in 
colour and no prediction of crystal habit could be made from the bulk sample. An initial 
solubility screen showed ASH89 to be soluble in methanol, acetonitrile, ethanol, DMSO, 
ethyl acetate and chloroform and partially soluble in ethylene glycol, cyclohexane, 1-
pentanol, heptane, 1-hexanol and decane. Although the sample was soluble in several 
solvents, not all were suitable for crystal growth. For example, when dissolved in both 
methanol and acetonitrile, oil was produced upon evaporation of the solvents.   
 
 
Figure 4.1|  Clusters of ASH89 crystals grown via evaporation of solvent, ethylene glycol. Needles 
were thin, approximately a width of <10 µm. 
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After three days at room temperature crystal growth was observed on the initial 
solubility screen slide for the sample dissolved in ethylene glycol and in DMSO. In DMSO a 
network of fine, wispy needles were formed from which no single crystal could be isolated. 
The formation of disordered crystals may be due to too rapid crystal growth upon a high 
rate of solvent evaporation. When dissolved in ethylene glycol, crystals of the tri-peptide 
grew in clusters of needles (Figure 4.1). The clusters were small, with needles approximately 
10 µm in width and 50 µm in length. Clusters of crystals are not suitable for X-ray diffraction 
experiments; therefore a paper taper was used to separate the clusters to try and isolate a 
single crystal needle (Figure 4.2). Upon dispersion of the needle cluster, fragments of 
needles, which may potentially be suitable for X-ray diffraction experiments, were selected 
and carefully transferred to a drop of inert oil, Fomblin.  
 
Figure 4.2|  Cluster of ASH89 crystals that has been separated using a paper taper in an attempt to 
isolate single crystal needle for X-ray diffraction experiments.  
Needles were thin, approximately a width of <10 µm. 
 
Screening of the crystals found them to diffract weakly. Two crystal needles were 
tested but both were probably not of sufficient size. Testing the crystals on intense 
synchrotron beamlines available at resources such as Diamond Light Source LTS may have 
given better results for structure determination.  
 Attempts were made to grow larger crystals which may be suitable for X-ray 
diffraction experiments. Firstly, attempts were made to form a larger volume of ASH89 
saturated ethylene glycol solution by using a glass well plate in which larger volumes of 
solvent could be used. A supersaturated solution was achieved in 6 µl of ethylene glycol and 
again clusters of needle crystals were observed at the edge of the drop with the tip of the 
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needles protruding towards the centre of the drop. The needles present in the clusters grew 
length ways to a greater extent than those observed in the initial solvent screen; however, 
the width of the crystals was still too limiting for good quality diffraction. Another saturated 
drop of ethylene glycol was prepared and seeded with a needle originally grown for the 
initial solvent screen; a crystal which appeared to have the largest width was selected. This 
however did not lead to single crystal growth but clusters.   
 
4.1.2|  Crystallisation of ASH81/87 
 
The sample of ASH81/87, a white crystalline material, was observed to be soluble in 
methanol, acetonitrile, ethanol, DMSO, 1-pentanol, ethyl acetate and insoluble in water, 
cyclohexane, decane, hexane and toluene. Partial solubility was observed in ethylene glycol 
and 1-hexanol. As expected not all solvents lead to re-crystallisation of the compound upon 
evaporation of the solvent. Oil was formed upon evaporation of 1-pentanol, heptane and 
ethyl acetate. Two of solvents, ethanol and DMSO, gave a crystalline material from the 
evaporation of solvent leaving a ring of crystalline material on the initial solvent screen glass 
slide. Although crystalline, no single crystals were observed and crystal habit could not be 
predicted from the material gained from DMSO. However, the ring of crystalline material 
left upon evaporation of ethanol appeared to be in clusters of very small, thin needles, 
giving an indication of the compound’s potential crystal habit. 
 Needles were grown from the drop of ethylene glycol on the initial solubility 
screen glass slide stored at room temperature. The crystals grew in clusters of thin needles, 
less than 10 µm in width, after 36 hours. At this point the clusters of needles were 
extremely small; the slide was therefore left for a further two days at room temperature. 
This led to further lengthwise growth of the crystal needles in the clusters but no change in 
the width of the crystals was observed (Figure 4.3). The larger crystal clusters were carefully 
teased apart using acupuncture needles resulting in the isolation of single needles 
approximately 70 µm in length (Figure 4.4). Several attempts to isolate single crystals were 
required, rapidly depleting the number of potential crystals for experiment as the needles 
were extremely brittle and fractured effortlessly.  
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Figure 4.3|  Cluster of ASH81/87 needle crystals grown via evaporation of ethylene glycol at room 
temperature for three and a half days. Needles were very thin, approximately 5 µm. 
 
 
Figure 4.4|  An isolated needle of ASH81/87 grown via evaporation of ethylene glycol at room 
temperature for three and a half days. Needles were very thin, approximately 5 µm.  
 
Larger volumes of saturated ASH81/87 solutions in ethylene glycol were prepared in 
a glass well plate. Crystal growth was observed as seen on the initial solvent screen slide; 
clusters of needles grew over five days. There was little difference in the size of the clusters 
of needles, however more clusters were grown. Clusters were transferred to inert oil and 
attempts were made to isolate single needles for screening. Using single needles grown in 
the glass well plate from ethylene glycol, two saturated solutions were seeded. In ethylene 
glycol no single crystal growth occurred and the expected clusters of needles resulted. 
Seeding a saturated solution of ASH81/87 in DMSO resulted in the growth of numerous 
clusters of insignificant size for experimental use.  
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4.1.3|  Crystallisation of ASH82 
 
The initial solvent screen for ASH82, a birefringent compound, showed the compound to be 
soluble in a limited number of solvents including acetonitrile and ethyl acetate. Partial 
solubility in toluene, 1-pentanol and 1-hexanol was observed and the compound was 
insoluble in water, methanol, ethanol and decane. On the glass slide used for the initial 
screen, evaporation of acetonitrile led to the formation of a mesh of long, thin, fibre-like 
crystals. ASH82 displayed a low solubility in toluene; however addition of the bulk sample to 
toluene lead to a separation of the material into what appeared to be single needles. These 
needles were far too small and fragile for analysis by X-ray diffraction. 
 Evaporation of 100% acetonitrile in a glass well plate lead to the same result as 
observed in the initial solvent screen. The mesh of fibre-like needles was transferred to 
another drop of acetonitrile and re-dissolved. Re-crystallisation did not occur. Similarly, 
crystal growth was not facilitated by evaporation of 100% toluene. Evaporation experiments 
were set up using a mixture of acetonitrile and toluene in ratios 1:1, 1:2 and 1:3. No single 
crystal growth resulted; therefore attempts were made to slow the rapid and abundant 
nucleation using liquid diffusion experiments. Water and decane were used as anti-solvents 
for ASH82 dissolved in acetonitrile. A 2:5 ratio of solvent to anti-solvent was used. After 
three weeks, no crystal growth had occurred for each of the liquid diffusion experiments; 
the solutions were allowed to evaporate, but still no crystal growth occurred.  
 
4.1.4|  Crystallisation of ASH90 
 
No crystal habit of ASH90, a birefringent solid, could be inferred upon initial observations 
under an optical microscope. The initial solvent screen found ASH90 to be soluble in 
acetonitrile, DMSO, and ethyl acetate, and partially soluble in 1-pentanol. Potential anti-
solvents may be selected from water, methanol, ethanol, ethylene glycol, cyclohexane, 
heptane, 1-hexanol, decane and hexane, in all of which ASH90 was observed to be insoluble. 
No crystal growth was observed for solvents in which ASH90 was readily soluble. Upon 
evaporation of 1-pentanol a ring of birefringent material was left deposited on the glass 
slide. No crystal habit could be predicted.  
 The liquid diffusion method was applied using a 2:5 ratio of ethyl acetate to hexane. 
However, very small clusters of needles were formed in a gel like manner which grew on the 
69 
 
side of the glass wall. This indicated that the compound was likely to crystallise in a bad 
habit unsuitable for structure determining X-ray diffraction experiments.  
 
4.1.5|  Crystallisation of ASH93 
 
A 3 mg sample of ASH 93, a white crystalline compound, was provided for crystallisation and 
subsequent structure determination. Potential anti-solvents were found to be water, 
methanol, ethanol, cyclohexane, 1-pentanol, hexane, heptane and decane. The compound 
was found to be soluble in a limited number of solvents including acetonitrile, DMSO, and 
ethyl acetate. Solutions of ASH93 in these three solvents were prepared in small glass vials 
with the lid partially open in attempt to slow evaporation rate. No crystal growth was 
observed for experiments conducted at room temperature and at 4 °C.  
 Vapour diffusion experiments were tested for each solvent using methanol, 1-
pentanol, cyclohexane and decane as an anti -solvent. This was an advantageous method 
for the small amount of material provided, requiring only three solutions of ASH93 which 
could easily be transferred to each of the anti-solvents. The vapour diffusion systems were 
closed and left for three days with each anti-solvent; however, no crystal growth resulted. 
 
4.1.6|  Crystallisation of ASH91 
 
The sample of ASH91 provided (2 mg) displayed a limited solubility in the solvents used in 
the initial solvent screen. Partial solubility was observed in acetonitrile, ethylene glycol 
(when gently heated), DMSO and ethyl acetate. DMSO was found not to be a promising 
solvent for crystal growth as evaporation of the solvent left an oily residue behind on the 
glass slide.  Evaporation of both acetonitrile and ethyl acetate left a small ring of a 
birefringent material, from which no deduction of the crystal habit could be made.  The 
ethylene glycol drop did not yield any crystals.  
 A similar approach was taken to that used in attempts to crystallise ASH93. Vapour 
diffusion experiments were set up for the two solvents and these were screened against 
each of the anti-solvents. Initially a 2:5 ratio of solvent to anti-solvent was used, but this did 
not yield any crystal growth, leading to the trial of a 2:9 ratio. Crystal growth did not occur 
through vapour diffusion experiments.  
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4.1.7|  Crystallisation of ASH59 
 
ASH59 was observed to be soluble in mainly polar solvents including methanol, acetonitrile, 
ethanol, DMSO, 1-pentanol, and ethyl acetate. ASH59 also showed partial solubility in larger 
alcohol solvents such as 1-hexanol. Potential anti-solvents were observed to be water, 
cyclohexane, heptane, decane and toluene. No crystal growth was observed from the initial 
solvent screen, and evaporation of methanol, acetonitrile, and 1-pentanol left a deposit of 
oil.  
 Evaporation experiments were conducted in a glass well plate with 20 µl of 100% 
DMSO which lead to the growth of clusters of needles that aggregated together as more 
solvent evaporated. This experiment was repeated and a cluster of needles removed and 
transferred to a drop of inert oil before aggregation of clusters prevented their isolation. 
Unfortunately, no single needle crystal of sufficient quality and size could be separated from 
the clusters for analysis by X-ray diffraction. No evaporation experiments were conducted 
for methanol or ethanol as at room temperature these solvents evaporate too quickly.  
 Vapour diffusion experiments were set up for ASH59 dissolved in both methanol 
and acetonitrile, exploring several anti-solvents including water, cyclohexane and heptane. 
After two weeks no crystal growth was observed. Unfortunately, despite considerable 
effort, no crystals for ASH59 have yet been obtained for X-ray diffraction experiments.  
 
4.1.8|  Crystallisation of GDL02, GDL38 and GDL39 
 
Three birefringent compounds, GDL02, GDL38 and GDL39, yellow orange, yellow and orange 
in colour respectively, were provided for crystallisation and subsequent structural studies. 
All three compounds displayed similar results in the initial solubility screens, typically 
soluble in methanol, acetonitrile, ethanol, ethylene glycol, DMSO and toluene. Partial 
solubility was observed in water, ethyl acetate, 1-pentanol and 1-hexanol while typically the 
compounds were insoluble in cyclohexane, hexane, heptane and decane. Some variations in 
the solubility profiles of each compound were observed; GDL02 was insoluble in water, 
ethylene glycol and DMSO; GDL38 was partially soluble in toluene and GDL39 was soluble in 
ethylene glycol and 1-pentanol. 
 No crystallisation was observed on the initial solvent screen glass slides for each of 
the three molecules. However, when GDL02 was added to a drop of 1-hexanol, although 
only slightly soluble, small platelets with ill defined edges that had an oily appearance 
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appeared to grow out from the material that had not been dissolved. Evaporation of 25 µl 1-
1-hexanol in a glass well plate resulted in the formation of an oil upon evaporation of the 
solvent.  
 
4.2.|  Protein Crystallisation from Hanging Drop Vapour Diffusion Trays 
 
Crystals were observed in several drops of the crystallisation tray twelve hours after set-up. 
The differing conditions (pH of the reservoir solution and ratio of protein solution to 
reservoir solution in the hanging drop) resulted in different crystallisation outcomes 
including variation in the size and quality of crystals grown and the number of crystals 
grown per drop. After initial observation of crystal growth, the trays were stored at room 
temperature for a further 48 hours to allow the crystals present to grow larger. 
Crystallisation results from hanging drop vapour diffusion trays are summarised in Table 
4.1. 
 
Ratio for Protein solution(µl):Reservoir solution(µl) 
pH of Buffer 
solution 
3:1 2:1 3:2 2:2 1:2 1:3 
4.4 
Two, 
medium, 
single 
crystals. 
Two, 
medium, 
single 
crystals. 
Two, 
large, 
single 
crystals. 
Some 
crystalline 
material. 
No 
crystals 
No 
crystals 
4.8 
Some 
crystalline 
material. 
No 
crystals 
No 
crystals 
Large, 
single 
crystal. 
No 
crystals 
No 
crystals 
5.2 
Large, 
single 
crystal. 
Figure 4.6 
No 
crystals 
No 
crystals 
No 
crystals 
No 
crystals 
No 
crystals 
5.6 
Multiple, 
small, 
single 
crystals. 
Figure 4.5 
Multiple, 
small, 
single 
crystals. 
No 
crystals 
Some 
crystalline 
material. 
No 
crystals 
No 
crystals 
 
Table 4.1|  Crystallisation outcome of hanging drop vapour diffusion crystallisation tray stored at 
room temperature for 48 hours. The pH of the buffer solution and the protein to buffer solution ratio 
in the hanging drops were varied. 
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 Several of the drops were unsuccessful and no crystallisation resulted from vapour 
diffusion. Also, despite the occurrence of crystallisation in some of the drops, the crystalline 
material that resulted was not suitable for single crystal X-ray diffraction experiments. 
Drops with a pH of 5.6 and a 3:1 drop ratio of protein solution to reservoir solution resulted 
in the crystallisation of numerous small crystals which lacked the defined shape and edges 
required for the collection of a good X-ray diffraction data set (Figure 4.5). 
 
Figure 4.5|  Crystallisation outcome from hanging drop vapour diffusion tray in a well with reservoir 
solution of pH 5.6 and a hanging drop ratio of 3:1 of protein solution to reservoir solution. 
 
Single crystals were grown to a large size, approximately 500 µm x 750 µm, from 
several drops in the crystallisation tray. These crystals had well defined edges and displayed 
birefringence under polarised light (Figure 4.6). 
 
73 
 
 
Figure 4.6|  Crystallisation outcome from hanging drop vapour diffusion tray in a well with reservoir 
solution of pH 5.2 and a hanging drop ratio of 3:1 of protein solution to reservoir solution. 
 
Three repeats of the hanging drop vapour diffusion crystallisation tray were made 
and large, single crystals were harvested from wells of pH4.8 (drop ratio, 2:2) and wells of 
pH4.4 (drop ratio, 3:2) for X-ray diffraction experiments (the results of which are discussed 
in Section 4.6).  
 
4.3|  Bulk Anti-solvent Experiments 
 
Varying concentrations of NaCl solution (% by mass) were added to bulk 50 mgml-1 
Lysozyme solutions in 1:1 and 1:2 ratios of Lysozyme solution to NaCl solution. The 
crystallisation results of these bulk experiments are summarised in Table 4.2.  
 
 
50 mgml-1 Lysozyme in water: 
NaCl solution 
50 mgml-1 Lysozyme in 0.1M 
NaAc, pH 4.8: NaCl solution 
[NaCl] (% by 
mass) 
1:1 1:2 1:1 1:2 
1% 
No crystal 
growth 
No crystal 
growth 
No crystal 
growth 
No crystal 
growth 
5% Crystal growth Crystal growth Crystal growth Crystal growth 
10% 
Amorphous 
solid 
Amorphous 
solid 
Crystal growth 
Amorphous 
solid 
20% 
Amorphous 
solid 
Amorphous 
solid 
Amorphous 
solid 
Amorphous 
solid 
 
Table 4.2|  Crystallisation results from bulk anti-solvent experiments. 
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A 10-20% NaCl solution led to the rapid formation of a white amorphous solid when 
added to the Lysozyme solutions in both 1:1 and 1:2 ratios. However, crystal growth was 
observed when 10% NaCl was added in a 1:1 ratio to the Lysozyme in 0.1M NaAc, pH 4.8 
solution. The crystalline material grew quickly and was therefore disordered and irregular in 
shape. The addition of 1% NaCl solution did not facilitate crystal growth suggesting that 
supersaturation of the Lysozyme solution was not reached with this low NaCl 
concentration.  
A ratio of 1:1 and 1:2 with a 5% (wt) NaCl solution was found to be suitable for 
promoting growth of single Lysozyme crystals. Crystal formation was quicker with a ratio of 
1:2. However, little differentiation could be made between the quality of crystals obtained 
from both 1:1 and 1:2 ratios. Consequently, for direct addition of anti-solvent to 
microemulsion samples and for mixed microemulsion experiments, a 5% (wt) NaCl solution 
was typically used. 
 
4.4|  Protein Crystallisation from Microemulsions 
 
The below sections (Section 4.4.1 – 4.4.8) detail the crystallisation results for AOT, 
Span80/Brij30, Span80/Tween80, TX-114 and TX-100/1-hexanol surfactant systems. Results 
of varying the microemulsion method, including direct addition of anti-solvent, evaporation 
of the continuous phase and mixed microemulsion methods, are also discussed. 
 
4.4.1|  AOT Surfactant System  
 
Phase diagrams were constructed for AOT, an anionic surfactant, and comparisons were 
drawn between a dispersed phase of pure water and a 5% by mass NaCl solution. A NaCl 
solution of 5% by mass was chosen as this concentration was found to promote crystal 
growth of Lysozyme in bulk experiments with a ratio of both 1:1 and 1:2 for protein 
solution to salt solution. 
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Figure 4.7|  Ternary phase diagram constructed at room temperature for AOT, pure water and 
heptane. Markers indicate composition ratios which formed microemulsions. 
 
As depicted in Figure 4.7, a large region of stable microemulsions was possible for a 
dispersed phase of pure water. This usable region incorporated a large range of surfactant 
concentrations ranging from 10-50% by mass. The flexibility in composition of the three 
microemulsion components presented by an AOT surfactant system may therefore enable 
expansive variations in the microemulsions environment in order to find the niche 
composition that might enable Lysozyme crystallisation.  
In comparison, no stable microemulsions were formed for the tested compositions 
within a phase diagram when a solution of 5% (wt) NaCl was used as the dispersed aqueous 
phase. This restricted the flexibility for the design of mixed microemulsion experiments for 
the AOT surfactant system.  
A series of experiments were set up for the AOT surfactant system in which the 
Lysozyme concentration was varied. It was initially thought that it would be advantageous 
to prepare microemulsions on a small scale so that the methodology maintained the 
potential to be applied to the crystallisation of other proteins for which only small amounts 
of material were available. 
Consequently, microemulsions samples were prepared in 500 µl of both a 10% (wt) 
and 5% (wt) AOT/heptane solution. It was possible to incorporate a large range of Lysozyme 
concentrations into the 10% (wt) AOT surfactant system. However, Lysozyme solutions in a 
buffer of 0.1M NaAc of varying pH could not be dispersed in the surfactant system to form 
stable microemulsions. Table 4.3 summaries the samples which formed stable 
microemulsions with the 10% (wt) and 5% (wt) AOT in heptane surfactant systems and a 
dispersed aqueous phase of Lysozyme in water.  
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500 µl AOT 10% (wt) in heptane 500 µl AOT 5% (wt) in heptane 
Lysozyme 
concentration 
(mgml-1) 
Volume of 
aqueous phase 
(µl) 
Lysozyme 
concentration 
(mgml-1) 
Volume of 
aqueous phase 
(µl) 
50 10-40 50 10-20 
40 10-50 40 10-50 
30 10-50 30 10-50 
20 10-70 20 10-60 
10 10-100 10 10-60 
 
Table 4.3|  Samples which formed stable microemulsions prepared from the AOT surfactant system. 
 
No crystallisation was observed for single Lysozyme microemulsions. Therefore, 
experiments involving direct addition of the anti-solvent were set up in an attempt to 
facilitate crystal growth. Direct addition of 5% (wt) NaCl in 1:1, 1:2 and 1:0.5 ratios of 
microemulsion aqueous phase to anti-solvent solution to each of the microemulsions 
samples listed in Table 4.3 lead to phase separation. Subsequently, a methodology which 
did not involve an anti-solvent solution was applied. 
 Evaporation of the continuous phase was conducted on microemulsions that were 
prepared on a larger scale. The move to make microemulsions on a 2 ml scale as opposed 
to the previously used 500 µl scale was made because viewing the microemulsion samples 
via optical microscopy proved difficult for samples contained within such a small glass vial. 
Also, in anticipation of crystallisation, it was thought that a larger sample volume, and thus 
larger glass vial, would aid the crystal harvesting process and potentially produce larger 
crystals if more of the crystallisable material was contained within the microemulsions.  
 Table 4.4 lists the samples which formed stable microemulsions prepared from 2 ml 
of 10% (wt) AOT in heptane. Two repeats of the samples were made; for the first repeat no 
further experimental procedure was carried out and the samples were observed using an 
optical microscope to monitor crystallisation. The second repeat was used for experiments 
involving the evaporation of the continuous, heptane phase. Over a period of 16 hours the 
mass of each sample was reduced by approximately 15%. A third repeat of the samples was 
made; upon evaporation of the continuous phase the samples became cloudy and viscous 
when the mass of the samples was reduced by over 25%. No crystallisation of Lysozyme 
resulted from evaporation of the continuous phase.  
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Lysozyme concentration 
(mgml-1) 
Volume of aqueous phase 
(µl) 
30 20-200 
32 20-200 
34 20-200 
36 20-200 
38 20-200 
40 20-200 
42 20-200 
44 20-200 
46 20-180 
48 20-160 
50 20-160 
 
Table 4.4|  Samples which formed stable microemulsions in 2 ml of AOT 10% (wt) in heptane. Three 
repeats of these samples were made two of which were used for evaporation of the continuous 
phase experiments. 
 
Two methodologies, direct addition of an anti-solvent solution and evaporation of 
the continuous phase, failed to facilitate crystal growth from microemulsions using the AOT 
surfactant system. Mixed microemulsion experiments provide an alternative method; 
however, for the AOT surfactant system it was not possible to disperse NaCl solutions, 5-
10% by mass, to form stable microemulsions. In 1 ml of 10% (wt) AOT in heptane 10-40 µl 
of both a 1% and 0.5% (wt) NaCl solution was successfully dispersed. However, these NaCl 
concentrations, considering the initial bulk experiments, are not known to facilitate 
crystallisation of Lysozyme. Despite this, single Lysozyme microemulsions listed in Table 4.4 
were systematically combined with the NaCl microemulsions. No stable microemulsions 
were formed from the prepared mixed microemulsion samples.  
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4.4.2|  AOT Surfactant System: SAXS/GIFT Analysis 
 
A white precipitate was observed which formed immediately upon the addition of 
the aqueous Lysozyme solution to the surfactant system. However, once the sample was 
vortexed the precipitate was no longer observed and a transparent, colourless 
microemulsion was formed. To confirm that that precipitate was not being dispersed but 
was re-dissolving into the system, SAXS and subsequent GIFT analysis were applied to 
confirm the formation of microemulsion droplets.  
 
Figure 4.8|  Plot of      against   for single Lysozyme microemulsions consisting of 500 µl AOT 10% 
(wt) in heptane and a dispersed phase of either 10 µl of pure water or 10 µl of an aqueous Lysozyme 
solution of concentration 50 mgml
-1
. 
 
The formation of microemulsion droplets was confirmed by SAXS experiments 
(Figure 4.8) and by subsequent GIFT analysis which found the droplet for each sample to be 
within the expected size range for microemulsions. From Figure 4.9 it can be seen that the 
droplet radius increases when an aqueous Lysozyme solution is incorporated into the 
microemulsion system compared to when a dispersed phase of pure water is used. GIFT 
analysis found the radius to be 2.1 nm and 2.5 nm for a dispersed phase of pure water and 
of a 50 mgml-1 Lysozyme solution respectively. The confirmed presence of microemulsions 
droplets suggests that the white precipitate observed upon addition of the aqueous 
Lysozyme phase to the surfactant system is re-dissolved into the system upon vortexing of 
the sample.  
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Figure 4.9|  Pair distance distribution plot,     , for single Lysozyme microemulsions consisting of 
500 µl AOT 10% (wt) in heptane and a dispersed phase of either 10 µl of pure water or 10 µl of an 
aqueous Lysozyme solution of concentration 50 mgml
-1
. 
  
4.4.3|  Span80/Brij30 Surfactant System 
 
Following the success of glycine crystallisation from microemulsions4, samples of a similar 
nature were adapted for the application to Lysozyme crystallisation experiments. For the 
glycine experiments, 0.25g of aqueous phase in 7g of 40% Span80/Brij30 by mass in a 1:1 
ratio dissolved in heptane, formed stable microemulsions4. Applying this as a starting point 
for Lysozyme crystallisation experiments, it was found that 0.1-0.3g of 2.6 mgml-1 Lysozyme 
in water could be dispersed within 7g of the surfactant system to form stable 
microemulsions. No crystallisation occurred from the prepared samples. Lysozyme 
concentrations above 2.6 mgml-1 formed emulsions when the same microemulsion 
compositions were applied. 
Samples were prepared for varying concentrations of Lysozyme solution in the four 
buffers of differing pH. Only samples which incorporated an aqueous phase of Lysozyme 
solution in water formed stable microemulsions. No stable microemulsions were formed 
for the four buffer solutions of different pH.  
  It was possible to incorporate 0.1-0.3g of 1% (wt) NaCl solution into 7g of 40% by 
mass Span80/Brij30 in a 1:1 ratio dissolved in heptane. Mixed microemulsion samples were 
prepared, combining the single Lysozyme microemulsions and single NaCl microemulsions. 
All mixed samples formed emulsions and over time phase separated. If it was possible to 
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form stable mixed microemulsions from the single microemulsions mentioned, 
crystallisation may not have been expected based on the bulk anti-solvent experiments 
discussed in Section 4.3. The addition of a 1% (wt) NaCl solution to a 50 mgml-1 Lysozyme 
solution in both a 1:1 and 1:2 ratios did not lead to crystal growth. Thus formation of mixed 
microemulsions which incorporated a 1% (wt) NaCl in similar ratios and a Lysozyme solution 
much lower in concentration is not likely to achieve supersaturation within the 
microemulsions droplets and therefore subsequent crystallisation will not result. 
 It is also worth noting that at such a low Lysozyme concentration there will be 
approximately 1x1016 to 3x1016 Lysozyme molecules within each single microemulsion 
sample. Consequently, based on geometrical droplet size calculations, this would result in a 
Lysozyme molecule being present in 1 of approximately 3000 droplets. The probability of 
collisions between droplets containing Lysozyme molecules to form transient dimers for 
exchange of material and therefore support crystal growth is therefore significantly 
reduced. This may explain why no crystal growth occurred from the single Lysozyme 
microemulsions. However, this is of course assuming that the microemulsion droplets were 
supersaturated and nucleation had occurred.  
 
4.4.4|  Span80/Tween80 Surfactant System 
 
For the surfactant system Span80/Brij30 it was not possible to form stable microemulsions 
when Lysozyme was dissolved in a 0.1M NaAc buffer of varying pH. Consequently, in an 
attempt to explore an alternative surfactant system that would disperse the four buffer 
solutions, a Span80/Tween80 in heptane surfactant system was explored. A pseudo ternary 
phase diagram incorporating an aqueous phase of 0.1M NaAc buffer with a pH of 4.8 was 
established.  
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Figure 4.10|  Pseudo ternary phase diagram constructed at room temperature for Span80/Tween80 
(1:1), 0.1M NaAc buffer solution of pH 4.8 and heptane. Markers indicate composition ratios which 
formed microemulsions. 
 
 Only a small region of stable microemulsions (Figure 4.10) was formed. Stable 
microemulsions only formed with a low percentage by mass of aqueous phase, 
approximately 10%, and a surfactant concentration of approximately 40-60% by mass. 
Despite a small region of stable microemulsions, the surfactant system Span80/Tween80 
does allow dispersion of the buffer solution which will aid examination of the affect of pH 
on Lysozyme crystallisation from microemulsions.  Consequently, a series of samples were 
setup for the Span80/Tween80 surfactant system in which pH of the buffer solution and the 
Lysozyme concentration was varied. 
 It was found that for a solution of Lysozyme to be dispersed within the surfactant 
system to form stable microemulsions, a lower amount of surfactant was required 
compared to the amount thought to be required according to the pseudo ternary phase 
diagram (Figure 4.10). In 1 g of 20% by mass Span80/Teen80 in a 1:1 ratio dissolved in 
heptane, a maximum Lysozyme concentration of 2 mgml-1 could be dispersed to form 
stable microemulsions with each of the four buffer solutions. Prepared samples within this 
series of experiments which formed stable microemulsions are summarised in Table 4.5. No 
crystallisation resulted from the single Lysozyme microemulsions of varying buffer pH and 
Lysozyme concentration. 
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Lysozyme 
concentration 
(mgml-1) 
pH of buffer solution 
Volume of aqueous phase 
dispersed in 1 g of 20% (wt) 
Span80/Tween80 (1:1) in 
heptane (µl) 
1 
4.4 40-100 
4.8 20-120 
5.2 40-100 
5.6 40-100 
2 
4.4 50-90 
4.8 70-110 
5.2 60-100 
5.6 60-100 
 
Table 4.5|  Samples which formed stable microemulsions incorporating an aqueous phase of 
Lysozyme solutions in 0.1M NaAc buffer of varying pH within a surfactant system of 1 g 
Span80/Tween80 (1:1) 20% (wt) in heptane. 
 
 Consequently, in an attempt to increase the supersaturation of the microemulsion 
droplets, an experimental method was explored in which an anti-solvent solution of 5% (wt) 
NaCl was directly added to the single Lysozyme microemulsions listed in Table 4.5. The anti-
solvent solution was added 24 hours after initial formation of the single Lysozyme 
microemulsions. For each Lysozyme microemulsion, 5% (wt) NaCl solution was added in a 
1:1 and 1:2 ratio of microemulsion aqueous phase to anti-solvent solution. Direct addition 
of the anti-solvent solution in both 1:1 and 1:2 ratios led to the phase separation of the 
Lysozyme microemulsions. A ratio of 1:0.5 was thus conducted but this also led to phase 
separation.  
 Following this, mixed microemulsions were explored providing an alternative 
method for the facilitation of Lysozyme crystallisation by ensuring supersaturation within 
the microemulsion droplets was reached. A volume of 40-80 µl of 5% (wt) NaCl solution was 
successfully dispersed to form microemulsions in 1 g of 20% (wt) Span80/Tween80 in a 1:1 
ratio dissolved in heptane. Table 4.6 summarises the mixed microemulsion samples which 
formed stable microemulsions upon combining single Lysozyme and single anti-solvent 
microemulsions.  
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Aqueous phase 
volume ratio of 
single Lysozyme 
microemulsions to 
single anti-solvent 
microemulsions 
Lysozyme 
concentration 
(mgml-1) in single 
microemulsions 
pH of Lysozyme 
buffer solution 
Aqueous phase in 
single Lysozyme 
microemulsions (µl) 
1:1 
1 
4.4 40-80 
4.8 30-100 
5.2 40-90 
5.6 40-90 
2 
4.4 50-100 
4.8 40-90 
5.2 70-90 
1:2 
1 
4.4 40-50 
4.8 40-50 
5.2 40-50 
5.6 40-50 
2 
4.4 40-50 
4.8 40-50 
 
Table 4.6|  Summary of mixed microemulsion samples which formed stable microemulsions upon 
combing single Lysozyme and anti-solvent microemulsions. All single Lysozyme and anti-solvent 
microemulsions were made from 1 g of Span80/Tween80 in a 1:1 ratio, 20% (wt) dissolved in 
heptane, to which the stated volume of aqueous phase was added. 
 
 For the Span80/Tween80 surfactant system no crystallisation resulted from the 
mixed microemulsions. As thought with the Span80/Brij30 surfactant system this may be a 
consequence of the low Lysozyme concentration used. Such a low concentration of 
Lysozyme may mean that supersaturation within the microemulsions droplets is not 
reached even when an anti-solvent is introduced through mixed microemulsions. Also, 
assuming nucleation has occurred, few droplets within the microemulsions systems will 
contain Lysozyme molecules and therefore collisions between droplets to form transient 
dimers in support of crystal growth may be rare events. 
 
4.4.5|  TX100/1-hexanol and TX-114 Surfactant Systems: Phase Diagrams 
 
It has previously been reported that inclusion of electrolytes and additives such as acid, can 
affect the phase behaviour of microemulsions depending of the nature of the surfactant 
used176, 177. In some cases the affect of salt has been significant; phase separation has been 
reported178. Within this study previous surfactant systems (AOT, span80/Brij30 and 
span80/Tween80) have demonstrated such difficulties; their phase diagrams incorporating 
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a solution of electrolytes (NaCl solution of varying concentrations, % by mass) found either 
a very small or no area of stable microemulsion to be possible for varying compositions of 
the oil, aqueous and surfactant phases. An alternative surfactant system was sought that 
would enable a solution of NaCl to be utilised as the dispersed phase within a stable 
microemulsion. This was desirable in order to explore the application of the mixed 
microemulsion method to introduce an anti-solvent into the protein microemulsion in an 
attempt to increase supersaturation and mediate crystal growth.  
 Surfactant systems Triton X-100/1-hexanol and Triton X-114 offered a system that, 
compared with the other systems explored, enabled the largest region of stable 
microemulsion to be formed when a 5% (wt) NaCl solution was used as the dispersed 
phase. This was indicated through the preparation of their phase diagrams. Visualisation of 
the effect caused by the use of a NaCl solution was addressed by comparing the phase 
diagram incorporating 5% (wt) NaCl solution with an equivalent phase diagram in which 
pure water was used.  
 
 
Figure 4.11|  Pseudo ternary phase diagrams for TX-100/1-hexanol surfactant system with a 
continuous phase of cyclohexane and an aqueous phase of a) pure water b) 5% (wt) NaCl solution. 
Markers indicate composition ratios which formed microemulsions. 
 
 First examining the phase diagrams for the Triton X-100/1- hexanol system (Figure 
4.11) it can be clearly seen that replacement of pure water with 5% (wt) NaCl solution 
restricts the region in which stable microemulsions can be formed. The number of suitable 
compositions for the three microemulsion components is reduced by approximately two 
thirds.  Typically, for microemulsions containing a pure water dispersed phase, stable 
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microemulsions are formed with a low percentage by mass of aqueous phase, 
approximately 10-30%, and a high surfactant concentration, approximately 40-60% by 
mass. Use of 5% (wt) NaCl solution as the dispersed phase reduces the amount of aqueous 
phase that can be incorporated in a stable microemulsion to approximately 10% mass. To 
facilitate the formation of these stable microemulsions approximately 30-50% of surfactant 
is required.  
A similar result was observed for the Triton X-114 surfactant system (Figure 4.12). 
Using 5% (wt) NaCl solution as the dispersed phase led to a reduction in the compositional 
area in which stable microemulsions were formed. Stable microemulsions with a dispersed 
phase of pure water only formed when the aqueous phase contributed approximately 10% 
by mass of the whole microemulsion; however, a broad range of surfactant concentrations 
could be used, ranging from approximately 30-70% by mass. A dispersed phase of 5% (wt) 
NaCl solution achieved stable microemulsion with a percentage mass of approximately 
10%. The required surfactant concentration was shifted slightly higher to 40-80% compared 
to the phase diagram incorporating pure water. Unusually, the composition area for stable 
microemulsions was expanded when 5% (wt) NaCl solution was used instead of pure water.   
 
 
Figure 4.12|  Ternary phase diagrams for TX-114 surfactant system with a continuous phase of 
cyclohexane and an aqueous phase of a) pure water b) 5% (wt) NaCl solution. Markers indicate 
composition ratios which formed microemulsions. 
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4.4.6|  TritonX-114 Surfactant System 
 
Based on the initial results from the pseudo ternary phase diagram (Figure 4.12), samples 
were made in which Lysozyme solutions of varying concentrations were used for the 
aqueous, dispersed phase, replacing pure water. The phases of these samples are 
summarised in Table 4.7. Composition ratios found to form stable microemulsions in the 
pseudo ternary phase diagram typically also formed stable microemulsions when different 
Lysozyme concentrations were used in the aqueous phase. There were a few exceptions for 
the composition ratio 1:7:2 for which emulsions were formed with Lysozyme 
concentrations of 50 mgml-1 and 40 mgml-1. The microemulsions formed were monitored 
regularly using an optical microscope for a period of two months during which no 
crystallisation was observed. 
 
 Lysozyme concentration (mgml-1) 
Lysozyme solution: 
TX-114: 
Cyclohexane 
50 40 30 20 10 5 
1:4:5       
1:5:4       
1:6:3       
1:7:2 e e     
 
Table 4.7|  Phase results for samples prepared for the TX-114 surfactant system incorporating a 
Lysozyme solution of  varying concentrations (50-5 mgml
-1
) as the dispersed phase. An emulsion is 
indicated by ‘e’ and a microemulsion is indicated by ‘’. 
 
Subsequently mixed microemulsions were made in an attempt to facilitate crystal 
growth. The mixed microemulsions consisted of combing each of the samples listed in Table 
4.7 with each of the composition ratios that formed stable microemulsions when a 
dispersed phase of 5% (wt) NaCl solution was used. All mixed systems formed stable 
microemulsions and did not degrade into emulsions or phase separate over time. No crystal 
growth resulted from mixed microemulsions made for the TX-114 surfactant system.  
 
4.4.7|  TritonX-100/1-hexanol Surfactant System 
 
Composition ratios of the three microemulsion components that gave stable, transparent 
microemulsions were selected from the pseudo ternary phase diagram in which the 
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dispersed phase used was pure water. The aqueous solution was replaced by a solution of 
Lysozyme in water with varying protein concentrations for each of the selected composition 
ratios. The phases of the resultant samples are summarised in Table 4.8. Although able to 
form microemulsions with a dispersed phase of pure water, some compositions did not 
permit microemulsions regardless of Lysozyme concentration. A dependence on Lysozyme 
concentration was observed for some compositions, typically forming emulsions at higher 
Lysozyme concentrations. Only two composition ratios, 2:4:4 and 2:5:3, formed 
microemulsions with each concentration of Lysozyme used.  
 
 Lysozyme concentration  (mgml-1) 
Lysozyme solution: 
TX-100/1-hexanol 
(1:1): 
Cyclohexane 
50 40 30 20 10 5 
1:3:6       
1:4:5 e      
1:5:4 e e e e e  
1:6:3 e e e e e e 
1:7:2 e e e e e e 
2:4:4       
2:5:3       
2:6:2 e      
2:7:1 e e e e e e 
3:4:3 e e     
3:5:2 e e e e e e 
3:6:1 e e e e e e 
 
Table 4.8|  Phase results for samples prepared for the TX-100/1-hexanol surfactant system 
incorporating a Lysozyme solution of varying concentrations (50-5 mgml
-1
) as the dispersed phase.  
An emulsion is indicated by ‘e’ and a microemulsion is indicated by ‘’. 
 
 All samples were stored at room temperature; microemulsions listed in Table 4.8 
displayed no degradation towards forming emulsions over time. Examination, by eye and 
optical microscope, of all Lysozyme microemulsions showed no crystal growth after four 
weeks. The lack of crystal growth led to the application of the mixed microemulsion 
method and evaporation of continuous phase in an attempt to facilitate crystal growth 
from these samples. 
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4.4.8|  TritonX-100/1-hexanol Surfactant System: Mixed Microemulsions 
 
Given the phase results displayed in Table 4.8 a 2:5:3 ratio was selected for use in the 
mixed microemulsion method, as this composition formed stable microemulsions with all 
Lysozyme concentrations used.  
The mixture formed from combining protein and anti-solvent microemulsions has 
to be a stable microemulsion in order for thermodynamic control of crystallisation through 
3D nanoconfinement to be achieved. However, this is not to say that the two components 
of the mixture have to be microemulsions themselves. It may be possible to combine one 
stable microemulsion with a nano- or macro-emulsion and still form a stable microemulsion 
for the final mixture. This has been demonstrated through the use of the mixed 
microemulsion method in the crystallisation of glycine polymorphs4.  
 Mixed microemulsions were prepared for the TX-100 surfactant system, combining 
stable Lysozyme microemulsions of varying Lysozyme concentrations and a composition 
ratio of 2:5:3 with different compositions of a 5% (wt) NaCl, anti-solvent microemulsion. 
Table 4.9 summarises the phases that were formed upon mixing. Generally, a stable 
microemulsion was made from combining two stable microemulsions. Macro-emulsions 
(white and cloudy in appearance) were initially formed upon mixing the 1:4:5 and 1:5:4 
compositions of the 5% (wt) NaCl microemulsions with higher Lysozyme concentration 
microemulsions.  
 
Protein 
Microemulsion 
(2:5:3) 
5% (wt) NaCl microemulsion (aqueous: surfactant/co-surfactant: oil) 
Lysozyme 
concentration  
(mgml-1) 
1:3:6 1:4:5 1:5:4 2:3:5 
50  e e  
40  e e  
30  e e  
20   e  
10     
5     
 
Table 4.9|  Phase results for the mixed microemulsion method using a TX-100/1-hexanol surfactant 
system. An emulsion is indicated by ‘e’ and a microemulsion is indicated by ‘’. 
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Crystal growth was observed in the mixed microemulsions three days after mixing. 
Examination under an optical microscope found that after approximately two weeks no 
further crystal growth occurred. The crystallisation result varied according to the 
concentration of Lysozyme used and the composition ratio of the anti-solvent 
microemulsion. Three repeats of the mixed microemulsions were made; for each repeat the 
same crystallisation outcome was observed as summarised in Table 4.10 with related Figure 
4.15a-p. 
 
Protein 
Microemulsion 
(2:5:3) 
5% (wt) NaCl microemulsion (aqueous: surfactant/co-surfactant: 
oil) 
Lysozyme 
concentration  
(mgml-1) 
1:3:6 1:4:5 1:5:4 2:3:5 
5 
No crystal 
growth 
No crystal 
growth 
No crystal 
growth 
No crystal 
growth 
10 
No crystal 
growth 
No crystal 
growth 
No crystal 
growth 
No crystal 
growth 
20 Figure 4.15a Figure 4.15e Figure 4.15i Figure 4.15m 
30 Figure 4.15b Figure 4.15f Figure 4.15j Figure 4.15n 
40 Figure 4.15c Figure 4.15g Figure 4.15k Figure 4.15o 
50 Figure 4.15d Figure 4.15h Figure 4.15l Figure 4.15p 
 
Table 4.10|  Crystallisation results for mixed microemulsions prepared with the TX-100/1-hexanol 
surfactant system. 
 
For each anti-solvent composition ratio, no crystal growth was seen for Lysozyme 
concentrations of 10 mgml-1 and 5 mgml-1. For these concentrations of Lysozyme it is 
possible that the droplets are not supersaturated; therefore nucleation cannot take place 
and no crystal growth will occur. The amount of crystalline material increased as the 
concentration of Lysozyme used in the microemulsions was also increased. No single 
crystals with well defined edges were observed for the anti-solvent composition ratios 
1:3:6, 1:4:5 and 1:5:4.  
A sheet of crystalline material was formed over the bottom of the glass vial from 
samples which formed emulsions upon mixing. For low Lysozyme concentrations only small 
areas of crystalline material were observed surrounded by an amorphous material which 
appeared dark and dull under the microscope. As Lysozyme concentration was increased 
the sheet of crystalline material began to present some shape with rough, non-uniform 
edges. However, the connected nature of the sheet prohibited isolation.  
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For an anti-solvent composition ratio of 1:3:6, aggregates of crystalline material 
were formed when a Lysozyme concentration of 30-50 mgml-1 was used. As Lysozyme 
concentration was increased, the crystals began to grow into a shape similar to that 
observed in successful wells in the hanging drop vapour diffusion trays. For Lysozyme 
concentrations of 40 and 50 mgml-1, single needles seemed to grow outwardly from the 
aggregates of crystalline material (Figure 4.13). With great care these needles may be able 
to be separated from the crystalline aggregates and used for structural analysis. However, 
these needles are not of the crystal quality that would be typically selected for analysis. 
 
Figure 4.13|  Crystal grown from a mixed microemulsion composed from a single Lysozyme 
microemulsion with concentration 40 mgml
-1
 and a single NaCl, anti-solvent microemulsion with a 
composition ratio of 1:3:6. 
 
Single crystals were only observed for mixed microemulsions formed from a NaCl 
microemulsion with a composition ratio of 2:3:5. However, the nature of these single 
crystals varied depending on the concentration of Lysozyme used. For each Lysozyme 
concentration more single crystals were formed compared to the number of crystals which 
can be grown from one drop in the hanging drop vapour diffusion tray. The quality of single 
crystals formed improved as Lysozyme concentration was increased. The better quality 
crystals, approximately 500µm x 500µm x 300µm in size, with a well defined shape and 
edges, were obtained from a Lysozyme concentration of 50 mgml-1 (Figure 4.14). Crystals 
from this mixed microemulsion were used for subsequent X-ray diffraction experiments.  
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Figure 4.14|  Single crystals grown from a mixed microemulsion composed from a single Lysozyme 
microemulsion with concentration 50 mgml
-1
 and a single NaCl, anti-solvent microemulsion of 
composition ratio 2:3:5. 
 
A series of control experiments were conducted for the TX-100 surfactant system. 
Repeats of the mixed microemulsions were made in which for the first repeat the Lysozyme 
solution was replaced with pure water and the anti-solvent microemulsion kept the same. 
This would indicate there was salt, NaCl, crystallising out of the mixed microemulsions. A 
second repeat was made in which the 5% (wt) NaCl solution was replaced with pure water 
to see if Lysozyme would crystallise out from the mixed microemulsions in the absence of 
an anti-solvent. This would aid discussion as to whether the crystallisation of Lysozyme 
from mixed microemulsions was a result of an increased supersaturation or a function of 
droplet size. For all of the control experiments conducted, no crystallisation was observed 
and the phase behaviour observed was identical to that of the original mixed 
microemulsions.  
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Figure 4.15 |  Optical microscope images of crystalline material grown from mixed microemulsions formed from an anti-solvent microemulsion with composition ratio X:X:X 
and a single Lysozyme microemulsion (composition ratio 2:5:3) of concentrations as follows: 
a) 1:3:6, 20 mgml
-1
 b) 1:3:6, 30 mgml
-1
 c) 1:3:6, 40 mgml
-1
 d) 1:3:6, 50 mgml
-1
 e) 1:4:5, 20 mgml
-1
 f) 1:4:5, 30 mgml
-1
 g) 1:4:5, 40 mgml
-1
 h) 1:4:5, 50 mgml
-1
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Figure 4.15 |  Optical microscope images of crystalline material grown from mixed microemulsions formed from an anti-solvent microemulsion with composition ratio X:X:X 
and a single Lysozyme microemulsion (composition ratio 2:5:3) of concentrations as follows: 
i) 1:5:4, 20 mgml
-1
 j) 1:5:4, 30 mgml
-1
, k) 1:5:4, 40 mgml
-1
 l) 1:5:4, 50 mgml
-1
 m) 2:3:5, 20 mgml
-1
 n) 2:3:5, 30 mgml
-1
, o) 2:3:5, 40 mgml
-1
 p) 2:3:5, 50 mgml
-1
. 
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4.5|  TritonX-100/1-hexanol Surfactant System: Droplet Size Analysis 
 
The crystallisation results from mixed microemulsions varied depending on the 
concentration of Lysozyme used and the composition ratio of the NaCl, anti-solvent 
microemulsions. Variation in both the form and amount of the crystalline material was 
observed. SAXS experiments and subsequent GIFT analysis of the X-ray scattering data were 
used to aid discussion as to how such differences in crystallisation results correlate to the 
environment from which the crystalline material was grown. SAXS data was collected for 
mixed microemulsions composed of anti-solvent microemulsions with composition ratios 
1:3:6 and 2:3:5 and with Lysozyme microemulsions of concentration 50-0 mgml-1.  
 
4.5.1|  Varying Lysozyme Concentration in Single Microemulsions 
 
For comparison, the droplet sizes of the single microemulsions that were used to form the 
mixed microemulsions were also determined. Figures 4.16 and 4.17 show the scattering 
plots and pair distance distribution plots respectively, for microemulsions formed from a 
composition ratio of 2:5:3 of the TX-100/1-hexanol surfactant system with varying 
Lysozyme concentrations of 0-50 mgml-1. The samples diffracted well, showing that the 
aqueous phase had been successfully dispersed and confined, forming microemulsion 
droplets.  
 
Figure 4.16|  Plot of      against  , obtained from SAXS experiments for single microemulsions of 
the TX-100/1-hexanol surfactant system with composition ratio 2:5:3 and varying Lysozyme 
concentrations. 
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The formation of microemulsions was confirmed using GIFT analysis, which found 
droplets to be within the expected size range. The data collected fit a hard sphere model. 
As can be seen in Figure 4.17 and summarised in Table 4.11, there is little variation in the 
radius of microemulsion droplets as the Lysozyme concentration is varied. The slight 
differences in radius values calculated using GIFT analysis all occur within the expected 
error of ± 0.3 nm for SAXS experiments. This suggests that the radius of microemulsion 
droplets is not affected by the concentration of Lysozyme.  
 
Figure 4.17|  Pair distance distribution plot for single microemulsions of the TX-100/1-hexanol 
surfactant system with composition ratio 2:5:3 and varying Lysozyme concentrations. 
 
 
 
Lysozyme concentration (mgml-1) in single 
microemulsions with composition ratio 2:5:3 
50 40 30 20 10 5 0 
Mean droplet radius 
(GIFT) (nm) 
3.9 3.9 3.8 3.7 3.6 3.8 3.8 
No. of droplets in 
microemulsion (x 1018) 
1.43 1.45 1.51 1.64 1.75 1.54 1.56 
Normal mean No. 
Lysozyme molecules 
per droplet 
0.58 0.46 0.33 0.20 0.09 0.05 0 
 
Table 4.11|  GIFT analysis results for single microemulsions of the TX-100/1-hexanol surfactant 
system with composition ratio 2:5:3 and varying Lysozyme concentrations. 
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 Calculation of the geometric droplet size does not correlate with the droplet size as 
determined by GIFT analysis. However, for geometric calculations, lowering the mass of the 
co-surfactant, 1-hexanol, residing at the interface and subsequently increasing the mass of 
the continuous phase, leads to a calculated geometric droplet radius that is similar to the 
radius calculated by GIFT analysis. Table 4.12 summarises the radii of droplets predicted 
using geometric droplet size calculations depending on the amount of 1-hexanol taken to 
reside at the interface between the water and oil phases. Any 1-hexanol not thought be 
residing at the interface is taken to partition into the cyclohexane, oil phase. Reducing the 
mass of 1-hexanol that resided at the interface from 0.5g to approximately 0.25-0.27g, 
results in a closer agreement between the droplet radii calculated by geometric calculations 
and by GIFT analysis. 
 
 
1-hexanol (g) residing at the interface 
0.5 0.3 0.27 0.25 0.23 
Geometric 
radius (nm) 
2.7 3.6 3.8 3.9 4.1 
 
Table 4.12 |  Variation of geometrically calculated droplet size when the amount of 1-hexanol 
thought to reside at the interface between the aqueous and oil phases is varied. Calculations made 
for single microemulsions of the TX-100/1-hexanol surfactant system with composition ratio 2:5:3. 
 
4.5.2|  Varying Composition Ratio of Single Anti-solvent Microemulsions  
 
SAXS experiments confirmed that the aqueous phase (5% (wt) NaCl solution) was 
successfully confined within microemulsion droplets. Changes in droplet size are observed 
for the single anti-solvent microemulsions as the composition ratio (aqueous phase: 
surfactant/co-surfactant: oil phase) is varied. Figures 4.18 and 4.19 respectively show the 
scattering plots and pair distance distribution plots for single NaCl anti-solvent 
microemulsions with differing composition ratios. The scattering intensity increases 
significantly as the mass of the aqueous phase is doubled from 0.2 g to 0.4g. The slight dis-
symmetry observed in the      plots is thought to be caused by the polydispersity present 
among microemulsion droplets. The polydispersity observed may be a result of many 
factors including a slightly non-spherical shape which does not quite fit the hard sphere 
model, the formation of transient dimers and an inhomogeneous distribution of droplet 
sizes within the microemulsions sample78.  
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Figure 4.18|  Plot of      against   for single NaCl, anti-solvent microemulsions of different 
composition ratios, made using a TX-100/1-hexanol surfactant system. 
 
 
Figure 4.19|  Pair distance distribution plots for single NaCl, anti-solvent microemulsions of different 
composition ratios, made using a TX-100/1-hexanol surfactant system. 
 
For these four anti-solvent microemulsions, the largest droplet size is seen for a 
composition ratio of 2:3:5 and the smallest droplet size with a composition of 1:5:4 (Table 
4.13). The droplet radius is found to be larger for composition ratios that have a smaller 
surfactant/co-surfactant content. Larger droplets are also observed for microemulsions 
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with a larger amount of aqueous phase. As expected, the number of droplets present in the 
microemulsions increases as the radius of microemulsion droplets decreases. 
 
 
Composition ratio of  5% (wt) NaCl anti-solvent 
microemulsion 
1:3:6 1:4:5 1:5:4 2:3:5 
Mean droplet radius (GIFT) 
(nm) 
4.8 4.2 3.9 6.8 
No. of droplets in 
microemulsion (x 1018) 
0.85 1.51 2.20 0.45 
 
Table 4.13|  Radii of single anti-solvent microemulsions of different composition ratios, made using a 
TX-100/1-hexanol surfactant system. The radii were determined by SAXS experiments and 
subsequent GIFT analysis. 
 
As seen with the single Lysozyme microemulsions, the estimated droplet sizes from 
geometrical droplet calculations do not correlate closely to the radii values calculated using 
GIFT analysis. Varying the amount of co-surfactant, 1-hexanol, which resides at the 
interface leads to a closer correlation between the two calculations of droplet size. 
However, there is variation in the percentage reduction of 1-hexanol at the interface (and 
thus subsequent increase in the mass of continuous phase) for each composition ratio of 
the NaCl microemulsions (Table 4.14) 
 
 
Composition ratio of  5% (wt) NaCl anti-
solvent microemulsion 
1:3:6 1:4:5 1:5:4 2:3:5 
Mean droplet radius 
(GIFT) (nm) 
4.9 4.2 3.9 6.8 
Total 1-hexanol in 
microemulsion (g) 
0.3 0.4 0.5 0.3 
Estimate of 1-hexanol at 
the interface (g) 
0.07 0.09 0.105 0.08 
% reduction of 1-hexanol 
at the interface 
76.7 77.5 79.0 73.3 
Geometric radius (nm) 4.8 4.2 4.0 6.9 
 
Table 4.14|  The percentage reduction of 1-hexanol required to bring the estimated droplet size, as 
determined using geometric droplet size calculations, into closer correlation with the experimentally 
determined droplets size using SAXS experiments and subsequent GIFT analysis for single NaCl, anti-
solvent microemulsions of different composition ratios, made using a TX-100/1-hexanol surfactant 
system. 
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4.5.3|  Droplet Sizes of Mixed Microemulsions 
 
SAXS experiments were conducted for mixed microemulsions composed of single Lysozyme 
microemulsions of concentration 50-5 mgml-1 and single anti-solvent microemulsions with 
composition ratios 1:3:6 and 2:3:5. SAXS data could not be collected for mixed 
microemulsions which incorporated single anti-solvent microemulsions with composition 
ratios 1:4:5 and 2:3:5 as the majority of these samples formed emulsions which have a 
droplet size larger than the detectable particle size for SAXS experiments. Confinement of 
the aqueous phase within the mixed microemulsions was confirmed through the scattering 
of X-rays by the samples as shown in Figure 4.20 and 4.21. Droplet sizes for all the mixed 
microemulsion samples were found to be within the expected 1-100nm range. 
 
 
Figure 4.20|  Plot of      against   for mixed microemulsions of the TX-100/1-hexanol surfactant 
system, composed of single Lysozyme microemulsions with composition ratio 2:5:3 and varying 
Lysozyme concentration and of single anti-solvent microemulsions with composition ratio 1:3:6. 
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Figure 4.21|       against   plot for mixed microemulsions of the TX-100/1-hexanol surfactant 
system, composed of a single Lysozyme microemulsion with composition ratio 2:5:3 with varying 
Lysozyme concentration and a single anti-solvent microemulsion with composition ratio 2:3:5. 
 
From GIFT analysis, Figures 4.22 and 4.23 and Table 4.15, it can be seen that the 
variation in Lysozyme concentration in the mixed microemulsions does not have a 
significant effect on the microemulsion droplet size. The slight variation in droplet size as 
the concentration of Lysozyme is varied falls within the error of ± 0.3 associated with SAXS 
experiments for both the 1:3:6 and 2:3:5 composition ratios. However, a reasonable 
difference in mixed microemulsion droplet size is observed when anti-solvent 
microemulsions of different composition ratios are used. Larger microemulsions droplets 
are observed for mixed microemulsions composed of an anti-solvent microemulsion with a 
composition ratio 2:3:5. This trend is observed independent of Lysozyme concentration.  
Using small angle X-ray diffraction measurements, Krigbaum found the radius of 
gyration,   , of Lysozyme to be 14.3 Å in solution
179. This can be approximated to a radius 
of 0.9 nm. Therefore, incorporation of Lysozyme into the aqueous dispersed phase will not 
perturb the mean droplet size, as determined by GIFT, as droplets sizes of the mixed 
microemulsions of the TX-100/1-hexanol surfactant system were found to be considerably 
larger than the approximate radius of Lysozyme. 
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Figure 4.22|  Pair distance distribution plots for mixed microemulsions of the TX-100/1-hexanol 
surfactant system, composed of single Lysozyme microemulsions with composition ratio 2:5:3 with 
varying Lysozyme concentration and of single anti-solvent microemulsions with composition ratio 
1:3:6. 
 
Figure 4.23|  Pair distance distribution plots for mixed microemulsions of the TX-100/1-hexanol 
surfactant system, composed of a single Lysozyme microemulsion with composition ratio 2:5:3 with 
varying Lysozyme concentration and a single anti-solvent microemulsion with composition ratio 
2:3:5. 
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Lysozyme concentration (mgml-1) in single 
microemulsions with composition ratio 1:3:6 
50 40 30 20 10 5 
Mena droplet radius 
(GIFT) (nm) 
4.6 4.5 4.6 4.5 4.6 4.5 
No. of droplets in 
microemulsion (x 1018) 
2.94 3.02 2.80 3.05 2.78 2.95 
Normal mean No. 
Lysozyme molecules 
per droplet 
0.28 0.22 0.18 0.12 0.06 0.03 
 
Table 4.15|  GIFT analysis results for mixed microemulsions of the TX-100/1-hexanol surfactant 
system, composed a single anti-solvent microemulsions with a composition ratio of 1:3:6 and single 
Lysozyme microemulsions of varying concentration. 
 
 
Lysozyme concentration (mgml-1) in single 
microemulsions with composition ratio 2:5:3 
50 40 30 20 10 5 
Mean droplet radius 
(GIFT) (nm) 
5.4 4.9 5.2 5.0 5.3 5.2 
No. of droplets in 
microemulsion (x 1018) 
2.10 2.75 2.25 2.62 2.17 2.27 
Normal mean No. 
Lysozyme molecules 
per droplet 
0.39 0.24 0.22 0.13 0.08 0.04 
 
Table 4.16|  GIFT analysis results for mixed microemulsions of the TX-100/1-hexanol surfactant 
system, composed a single anti-solvent microemulsions with a composition ratio of 2:3:5 and single 
Lysozyme microemulsions of varying concentration. 
 
 As seen with the single microemulsions of the TX-100/1-hexanol surfactant system, 
the mixed microemulsions also require a reduction in the amount of 1-hexanol thought to 
reside at the interface between the oil and aqueous phases in order for a correlation to be 
seen between predicted radii values using geometric calculations and radii values 
determined experimentally. Table 4.17 details the estimated mass of 1-hexanol through to 
reside at the interface with the corresponding droplet radii values for mixed 
microemulsions incorporating anti-solvent microemulsions with composition ratios 1:3:6 
and 2:3:5. A percentage reduction of approximately 60-65% in the mass of 1-hexanol is 
required for mixed microemulsions incorporating anti-solvent microemulsions with 
composition ratio 1:3:6 and approximately 55-63% for microemulsions incorporating anti-
solvent microemulsions with composition ratio 2:3:5. 
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Composition 
ratio of anti-
solvent 
microemulsion 
Total 1-hexanol 
in mixed 
microemulsion 
(g) 
 
1:3:6 0.8 
Estimate of 1-
hexanol at the 
interface (g) 
0.28 0.29 0.30 0.31 
Geometric radius 
(nm) 
4.7 4.6 4.5 4.5 
% reduction of 1-
hexanol at the 
interface 
65.00 63.75 62.50 61.25 
2:3:5 0.8 
Estimate of 1-
hexanol at the 
interface (g) 
0.30 0.32 0.34 0.36 
Geometric radius 
(nm) 
5.3 5.1 5.0 4.8 
% reduction of 1-
hexanol at the 
interface 
62.50 60.00 57.50 55.00 
 
Table 4.17|  The percentage reduction of 1-hexanol required to bring the estimated droplet size, as 
determined using geometric droplet size calculations, into closer correlation with the experimentally 
determined droplets size using GIFT analysis for the mixed microemulsion systems of the TX-100/1-
hexanol surfactant system. 
 
4.6|  Single Crystal X-ray Diffraction Experiments 
 
Single crystals grown from both hanging drop vapour diffusion trays and mixed 
microemulsions were subject to X-ray diffraction experiments. An assessment of the data 
quality was made for the data collection of each single crystal as a means of comparing the 
quality of crystals grown from the two different crystallisation mediums. On average, 
crystals grown from each crystallisation method were the same size, approximately 0.4 mm 
x 0.3 mm x 0.2 mm as shown in Figure 4.24. 
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Figure 4.24|  Single crystal grown from a TX-100/1-hexanol mixed microemulsion composed of a 
single Lysozyme microemulsion with composition ratio 2:5:3, Lysozyme concentration of 50 mgml
-1
, 
and of a single anti-solvent microemulsion with composition ratio of 2:3:5. Approximately 0.4 mm x 
0.3 mm x 0.2 mm in size, the crystal is mounted and centred on the goniometer. 
 
 R-merge factors indicate data quality and thus internal consistency of the crystal. 
Consequently, R(int) values, the number of independent observations (redundancy) and 
I/sigma(I) values (computed for the entire data set as well as in resolution bins) of different 
data sets are commonly used to compare the quality of diffraction data. R(Int), a linear 
merging R-value, is the most commonly used data quality indicator used to indicated the 
general merging on identical, but otherwise unmerged, intensities. Here we discuss some of 
the quality and validation criteria for data used to solve macromolecular structures in X-ray 
crystallography for diffraction data obtained from crystals of Lysozyme grown in both 
standard hanging drop vapour diffusion trays and from mixed microemulsions.  
 The four single crystals were all found to have a primitive, tetragonal until cell. For 
the two crystals grown using hanging drop vapour diffusion trays, no statistically significant 
difference was observed in their unit cell parameters. However, for mixed microemulsion 
grown crystals, the parameters of their respective unit cells were found to have a 
statistically significant difference suggesting that the two crystals collected are different. 
The determination of unit cell parameters from rotation is not extremely accurate as the 
rotation angle is refined to optimise the quality of the data not the accuracy of the unit cell 
parameters. Analysis of several high-resolution protein structures180 revealed that 
considerable errors in the unit cell parameters were a common occurrence despite 
refinement during data processing. 
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Table 4.18|  Data statistics for single Lysozyme crystals grown from hanging drop vapour diffusion 
trays in which the pH of the reservoir buffer solution and the hanging drop ratio (protein solution: 
reservoir solution) were both varied. 
 
 Crystals grown from mixed microemulsion 
Crystal 1 Crystal 2 
Temperature (K) 100 100 
Crystal System Tetragonal Tetragonal 
Space Group P4(3)2(1)2 P4(3)2(1)2 
a  (Å) 76.901 78.049 
b (Å) 76.901 78.049 
c  (Å) 37.249 37.262 
α  (°) 90.00 90.00 
β  (°) 90.00 90.00 
γ  (°) 90.00 90.00 
Volume (Å3) 220282.34 226983.38 
Resolution (Å3) 1.80 1.61 
Mean I 22.5 19.3 
Mean I/Sigma 28.86 23.36 
R(Int) 0.0494 0.0403 
R(Sigma) 0.0269 0.0296 
Redundancy 8.15 5.56 
% Complete 99.3 97.2 
 
Table 4.19|  Data statistics for two single Lysozyme crystals grown from a TX-100/1-hexanol mixed 
microemulsion composed of a single Lysozyme microemulsion with composition ratio 2:5:3, 
Lysozyme concentration of 50 mgml
-1
, and of a single anti-solvent microemulsion with composition 
ratio, 2:3:5. 
 Crystals grown from hanging drop vapour 
diffusion tray 
pH 4.8, 2:2 pH 4.4, 3:2 
Temperature (K) 100 100 
Crystal System Tetragonal Tetragonal 
Space Group P4(3)2(1)2 P4(3)2(1)2 
a  (Å) 78.408 78.814 
b (Å) 78.408 78.814 
c  (Å) 36.880 36.790 
α  (°) 90.00 90.00 
β  (°) 90.00 90.00 
γ  (°) 90.00 90.00 
Volume (Å3) 226732.61 228530.00 
Resolution (Å3) 1.80 1.60 
Mean I 25.7 23.7 
Mean I/Sigma 35.85 48.55 
R(Int) 0.0399 0.0258 
R(Sigma) 0.0225 0.0150 
Redundancy 8.54 7.64 
% Complete 99.3 98.4 
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Common indicators of data quality for Lysozyme crystals grown in hanging drop 
vapour diffusion trays and via mixed microemulsions are listed in Tables 4.18 and 4.19 
respectively. Similar results were obtained for each data set collected from each of the four 
Lysozyme crystals. The values obtained were typical for a data collection of a test protein, 
Lysozyme, from the diffractometer used. For crystals grown in both crystallisation media 
explored in this thesis, R-values within the expected range were obtained. However, for the 
crystal grown in a hanging drop of pH 4.4 and hanging drop ratio of 3:2, a slightly low R(Int) 
value was observed. This may be associated with the slightly lower redundancy of the data 
set. Alternatively, the low R(Int) value may be an artefact of the freezing of the crystal in 
the cryo stream which differs for each crystal tested.  
The minimal differences observed between each data set may be accounted for by 
differences in freezing of each Lysozyme crystal in the cryo stream. The setup of the 
diffractometer should also be considered. Due to the availability of the diffractometer the 
data sets were not conducted consecutively. Over time, water condensation can build 
between the Phosphor layer and the glass plate of the detector. This results from the 
difference in temperature as the CCD chip is cooled to -60°C. Consequently, the recorded 
intensity of the X-rays hitting the detector may be above or below the expected intensity. 
This can be seen using a spatial distribution of (I-<I>)/su plot, Figure 4.25, which indicates in 
red and blue, intensities that are observed to be above and below the expected intensity 
respectively.  
 
Figure 4.25|  Spatial distribution of (I-<I>)/su from data set collected from crystal grown using 
hanging drop vapour diffusion, with reservoir solution pH 4.4 and hanging drop ratio, 3:2. Red and 
blue points respectively indicate intensities that are observed to be above and below the expected 
intensity. 
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Over the period of which the four data collections were conducted this was found to be the 
case. This may contribute to the differences in data quality for each of the four Lysozyme 
crystals exposed to X-ray diffraction experiments. Subsequently, the diffractometer has 
been serviced and the condensation between the phosphor layer and glass plate has been 
addressed. 
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Chapter Five 
Conclusions 
 
In this thesis the crystallisation from microemulsions of a commonly used standard protein, 
Lysozyme, was compared to its crystallisation using a standard technique, hanging drop 
vapour diffusion. An assessment of the resultant Lysozyme crystals grown from each 
crystallisation medium was made with the aid of single crystal X-ray diffraction 
experiments. Previously, microemulsions have been utilised in the successful crystallisation 
of small molecules only such as ROY3 and glycine4. Here, it is shown, for the first time that 
the novel microemulsion methodology can be successfully used for the crystallisation of 
proteins, extending the methods towards macromolecular crystallography.  
Several surfactant systems were explored and variations of the microemulsion 
method exploited in an attempt to crystallise Lysozyme under thermodynamic control using 
3D nano-confinement in microemulsions. The five surfactant systems used include 
Span80/Brij30, Span80/Tween80, AOT, TX-114 and TX-100/1-hexanol. Three variations of 
the microemulsion method were made: direct addition of anti-solvent (an aqueous NaCl 
solution was used), the mixed microemulsion method and evaporation of the continuous 
phase. SAXS experiments were conducted to confirm the formation of microemulsions 
through the occurrence of X-ray scattering and subsequent determination of the droplet 
size using GIFT analysis.  
To aid the assessment of the quality of Lysozyme crystals grown using 
microemulsions a standard hanging drop vapour diffusion tray was utilised to grow 
Lysozyme crystals of a typically expected quality for single crystal X-ray diffraction 
experiments. In these standard trays the pH of the reservoir solutions and the ratio of the 
50 mgml-1 Lysozyme solution and reservoir solution within the hanging drop were varied.  
 A Bruker MicroStar diffractometer was used for the screening of crystals and for 
data collection of crystals grown from both hanging drop vapour diffusion and 
microemulsions. An evaluation of the collected data sets was made through comparison of 
key indicators of data quality commonly published within the crystallographic “table 1”. 
From the quality of each data set a comparative assessment of crystal quality was made for 
crystals grown by both protein crystallisation mediums explored within this thesis.  
Demonstrating the success of a commonly used crystallisation technique, Lysozyme 
crystals were grown using a hanging drop vapour diffusion tray. Crystals of a high quality 
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used for X-ray diffraction experiments were grown from a reservoir solution of pH 4.8 and 
4.4 with hanging drop ratio 2:2 and 3:2, respectively. Not all crystallisation conditions in the 
individual wells were successful and the quality (as judged by eye) and number of crystals 
present in successful wells varied across the tray (Table 4.1). Crystallisation may not have 
occurred because of several influencing factors; most likely, supersaturation was not 
reached. The growth of several smaller crystals within the same drop may be a result of 
nucleation occurring later on in the supersaturated metastable region resulting in the 
formation of numerous critical nuclei and thus growth of several small crystals (as shown in 
the crystallisation phase diagram, Figure 2.15). As expected, in light of extensive previous 
work on the crystallisation of Lysozyme13, single Lysozyme crystals of a good quality could 
be successfully and reliably grown using the hanging drop vapour diffusion trays. 
Of the several surfactant systems explored, not all were successful in supporting 
the crystallisation of Lysozyme despite being shown to form microemulsions by SAXS 
experiments and subsequent droplet size determination. Unsuccessful systems typically 
incorporated either or both a small Lysozyme concentration (less than 3 mgml-1) and/or a 
small volume of aqueous phase. In these circumstances, crystallisation may not occur due 
to supersaturation not being obtained within the microemulsion droplets on account of the 
low Lysozyme concentrations. In cases where supersaturation may have been reached and 
nucleation within the droplets has taken place, the slow rate of droplet collision due the 
limited amount of aqueous phase incorporated in the microemulsion system may inhibit 
crystal growth.  
The TX-100/1-hexanol surfactant system was found to be most successful system, 
and therefore the system of choice, successfully crystallising Lysozyme when the mixed 
microemulsion methodology was applied. The quality, morphology and quantity of 
Lysozyme crystals were found to vary with the composition ratio of the single anti-solvent 
(5% (wt) NaCl solution) microemulsions and the concentration of Lysozyme in the single 
protein microemulsion of composition ratio 2:5:3. Lysozyme crystals of the most suitable 
quality, as judged by eye and later shown through diffraction experiments, for single crystal 
X-ray diffraction experiments were obtained from a mixed microemulsion with a Lysozyme 
microemulsion of concentration 50 mgml-1 and a NaCl, anti-solvent microemulsion of 
composition ration 2:3:5. Crystallisation from this mixed microemulsion gave numerous, 
good quality crystals in one sample. This result was successfully repeated.  
The use of SAXS experiments on microemulsion samples proved highly valuable, 
confirming the formation of microemulsions through the occurrence of X-ray scattering and 
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the subsequent determination of droplet sizes using GIFT analysis, all of which fell within 
the expected 1-100 nm range for microemulsions. Interestingly for both the TX-114 and TX-
100/1-hexanol surfactant system it was found that to bring the geometrically calculated 
droplet size and the GIFT calculated droplet size into correlation a reduced amount of 1-
hexanol thought to partition at the oil/water interface was required in the geometric 
calculations.  
Key indicators of data quality, including R-values and redundancy, were similar for 
each data set collected from single Lysozyme crystals grown from both hanging drop 
vapour diffusion trays and microemulsions, a new methodology for protein crystallisation 
presented in this thesis. Using the Bruker MicroStar diffractometer, data sets of an equally 
good quality can be collected from single Lysozyme crystals grown from the two 
crystallisation mediums discussed in Sections 4.2 and 4.4.8. The data sets collected are of a 
publishable quality, with the values of common data quality indicators being within the 
ranges found and expected within literature181-183. This demonstrates that microemulsions 
provide a novel methodology for protein crystallisation producing crystals of a quality 
commonly found using standard techniques.  
Crystallisation remains the bottle neck for structural analysis of proteins1, 
particularly proteins for which structural information is vital for structure based drug design 
of these key targets. While structures of some targets are known184-187, many remain to be 
determined. Ideally, the development of a generic methodology for protein crystallisation 
will help relieve the bottle neck in crystallisation, particularly for proteins which display 
polymorphism. This would be advantageous for pharmaceutical companies which may 
require the most thermodynamically stable form of a peptide drug, a type of drug which is 
being increasingly being developed as therapeutic mediums188. To this end, further work 
should be carried out in which the microemulsion method, used for the crystallisation of 
Lysozyme in this thesis, should be applied to the crystallisation of different model proteins. 
Proteins such as Insulin, glucose isomerase and albumin would be well suited for this task. 
Alternative surfactant systems may be required and their crystallisation may or may not 
require the use of mixed microemulsions as was seen for Lysozyme crystallisation.  
Expanding the microemulsion technique to the crystallisation of membrane 
proteins may require the development of an oil in water microemulsion system as a result 
of the hydrophobic nature of membrane proteins. Complications may arise for 
transmembrane proteins which consist of both hydrophobic and hydrophilic moieties. The 
isolation and purification of membrane proteins through the use of detergent/surfactant 
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molecules often leads to protein/detergent complexes. The incorporation of these 
complexes into a microemulsion system may see the complex residing at the interface of 
the dispersed and continuous phases due to the presence of detergent molecules. SAXS and 
subsequent GIFT analysis may be used to confirm formation of microemulsions and 
determine droplets size, it may also be possible to decipher where the membrane protein 
partitions within the microemulsion structure, either in the oil or water phases or at their 
interface.  
Several potential membrane proteins and membrane spanning peptides could be 
utilised in order to explore the use of microemulsions for their crystallisation. In particular 
the 25 residue, membrane-spanning part of the M2 protein of the influenza virus would be 
an interesting starting point due to its biological importance as a target of anti-influenza 
drugs, amantadine and rimantadine189. The M2 peptide is well suited for systematic 
crystallisation studies as the crystallisation conditions for the wild-type peptide are known, 
thus serving as a benchmark for crystal quality. Also, although the peptide is soluble in 
aqueous solution it inserts itself into biological membranes and therefore behaves like a 
small integral membrane protein. Through the use of microemulsions for the crystallisation 
of resistant determining variants of the M2 peptide there is prospect in gaining further 
insight into one of the resistance mechanisms of the influenza virus. Further still, 
microemulsions could be applied to the crystallisation of bacteriorhodopsin for which 
crystallisation conditions are known, again serving as a benchmark for crystal quality.  
Microemulsions had previously only been applied to the crystallisation of small 
molecules, glycine and ROY; in this thesis microemulsions have been successfully used as a 
novel technique for crystallising the model protein, Lysozyme. The use of microemulsions to 
crystallise Lysozyme opens up a new avenue for macromolecular crystallography in 
attempts to relieve the “bottle neck” in crystallisation currently experienced within 
research concerning the structural exploration of proteins and membrane proteins.  
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Appendix 
 
A1|  Crystallisation Conditions for Different Crystal Forms of Lysozyme and Lysozyme 
Nitrate 
 
 Crystal form Crystallisation conditions 
Lysozyme 
Monoclinic 
1) 1.0 g HEWL dissolved in 10 ml aqueous solution 
containing 10% NaCI and 5% 1-propanol. The pH of the 
solution was adjusted to 7.6 with 0.1 M HCl at 313K125. 
  
Triclinic 
1) Sitting drop, vapour diffusion. 30 mgml-1 protein, 20 nM 
sodium acetate buffer, pH4.7. Well solution = 0.5 M 
NaNO3, 0.1 M sodium acetate buffer, pH4.7, 20% ethylene 
glycol. 1.5 µl drops of protein and well solutions were 
micro-seeded with crushed crystals of triclinic Lysozyme. 
Crystals grew at 292K over 5days190. 
 
2) D2O solution containing 1% (w/v) protein, 2% (w,v) NaNO3 
and 10 nM sodium acetate. Seed crystals were added to 
the protein solution and was allowed to stand at 313K191. 
 
3) Triclinic form II was formed by transformation of form I by 
its exposure to a dry nitrogen gas stream at 263K191. 
 
Hexagonal 
1) Solid sodium bicarbonate added to 10% (v/v) aqueous 
acetone solution until pH8.4. Solution saturated with 
NaNO3, final protein concentration of 25 mgml
-1 at 293K13. 
 
Orthorhombic 
1) Batch method. 500 mg HEWL in 5 ml water. 0.625 ml of 
0.3M acetate buffer, pH4.7 and 1.875 ml of water. 7.5 ml 
of 100 mgml-1 NaCl solution. Crystals obtained in two 
days192. 
 
2) Hanging drop, vapour diffusion. Droplet solution = 40 
mgml-1 protein, phosphate buffer, pH6.5, 5% (w,v) NaCl. 
Well solution = phosphate buffer, pH6.5, 20% (w.v) NaCl. 
Crystals took approximately two weeks to grow193. 
 
Tetragonal 
1) Yeast extracts, Marmite, Promite and Vegimite using 
counter diffusion crystallisation194. 
 
2) Batch method. Equal volumes of protein solution (50  
mgml-1 Lysozyme solution in 50 mM sodium acetate at 
pH4.5) and of the precipitating agent (precipitant NaCl in 
the same buffer, which concentration varied: 0.6, 0.8, 1.0, 
and 2.0 M),both prepared at room temperature. Prior to 
crystallization, all solutions were filtered through 0.22 μm 
syringe filters (Millipore). Quasi two-dimensional glass 
cells used195. 
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Lysozyme 
nitrate 
Monoclinic 
1) Generally obtained in the absence of acetate buffer196. 
 
2) 1% protein solution adjusted to pH4.5 by addition of nitric 
acid, and 0.35 M sodium nitrate at room temperature196. 
 
3) 3% protein solution in 0.23 M sodium nitrate at pH4.5 at 
4°C an 23°C. Nature of buffer missing but thought most 
likely to be acetate to fix pH4.5196. 
 
4) 0.2 M NaNO3, 50 mM acetate buffer, pH4.5 in light and 
heavy water solutions196, 197. 
 
Triclinic 
1) 0.2 M NaNO3, 50 mM acetate buffered solution, pH4.5, 
light water196. 
 
2) 30 mgml-1 of protein, acetate buffer, pH4.5. Monoclinic 
forms initially at 23°C, stable for weeks-months. 
Monoclinic crystals dissolve slowly as triclinic begin to 
form196. 
 
3) 7 mgml-1 of protein, 0.2-0.3 M NaNO3, 50 mM acetic acid/ 
Na acetate buffer, pH4.5, stored overnight at 4°C 
(precipitation step), triclinc crystals begin to form over a 
few days at 18°C196. 
 
4) <5 mgml-1 (3.4 and 3.0 mgml-1) protein, 4°C precipitation 
step, seeded at 18.5°C with triclinic crystals, kept at 
18.5°C for four weeks196. 
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A2|  Preparation of Compounds Subjected to Chemical Crystallisation 
 
 
  
Compound Amino acid sequence Preparation 
ASH81/87 Boc-SerArF-OBn 
Made from Boc-L-Ser-OBn with 
pentafluoropyridine and K2CO3 (Base) 
ASH91 Fmoc-Ser(tbu)-SerArF-OBn 
Boc-SerArF-OBn (ASH 81/87) was treated 
with trifluoroacetic acid (TFA) to remove 
Boc protection to yield: H-SerArF-OBn 
which was coupled to Fmoc-Ser(tBu)-OH 
with PyBOP (activator) and NMM (base) 
ASH93 Fmoc-Cys(trt)-SerArF-OBn 
Boc-SerArF-OBn (ASH 81/87) was treated 
with TFA to remove Boc protection to 
yield: H-SerArF-OBn which was coupled to 
Fmoc-Cys(trt)-OH with PyBOP (activator) 
and NMM (base) to yield: Fmoc-Cys(trt)-
SerArF-OBn (ASH 74). 
(ASH 74) was then treated with TFA to 
remove the trt protection from the 
cysteine. 
ASH59  
ASH 59 was a side product formed in the 
preparation of ASH81/87 
ASH82 Boc-SerArF-Ala-OBn 
Boc-SerArF-OBn was hydrogenated to 
deprotect the benzyl protection to yield 
Boc-SerArF-OH (ASH 80) 
Boc-Ala-OH was treated with benzyl 
bromide to yield Boc-Ala-OBn (ASH 79), 
ASH 79 was treated with TFA to remove 
the Boc protection and yield H-Ala-OBn 
(H-L-Ala-OBzl.HCl). 
This H-Ala-OBn (H-L-Ala-OBzl.HCl) was 
coupled to Boc-SerArF-OH (ASH 80) 
AH89 Boc-Ala-SerArF-Ala-OBn 
ASH 82 was treated with TFA to yield H-
SerArF-Ala-OBn, this was coupled to Boc-
Ala-OH to yeild ASH 89 
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